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ABSTRACT
The studies in this dissertation investigate neurodegenerative conditions
of the central and peripheral nervous system utilizing bioinformatics and systems
biology approaches. Various neurodegenerative conditions are associated with
neuroinflammation or the inflammation of nervous tissue. We utilized Parkinson’s
disease as our system for neuroinflammation in the central nervous system and
diabetic peripheral neuropathy for the peripheral nervous system. Parkinson’s
disease is associated with loss of dopaminergic neurons in the substantia nigra
and consequent loss of dopamine signaling in the striatum of the central nervous
system. Characteristics of Parkinson’s Disease include symptoms such as
shaking, rigidity, slowness of movement, difficulty walking, dementia, depression,
anxiety, sleeping disorders, and hallmark formation of misfolded α-synuclein
aggregates called Lewy bodies. Diabetic peripheral neuropathy is a
microvascular complication associated with diabetes mellitus. Degeneration of
the peripheral nervous system in diabetes presents as neuropathic pain in the
periphery with eventual loss of sensation in a stocking and glove like pattern. The
loss of sensation is an underlying cause of diabetic foot syndrome which is the
leading cause of lower limb amputations.
This dissertation consists of three studies. The first study compared
multiple murine models of diabetic peripheral neuropathy at different stages of
xv

the disease against human subjects in effort to identify an underlying cause of
disease using publicly available microarray transcriptomic data. Pathway and
network analysis were performed in conjunction on differentially expressed genes
identified by comparing healthy controls to diabetic mice and progressive to nonprogressive human subjects with diabetic peripheral neuropathy. Clusters of
pathways in this network were related to inflammation, degradation, apoptosis,
as well as kinase and immune signaling, as conserved changes across multiple
time points, models, and species of DPN. These observed pathways, commonly
disrupted across progression, species, and various murine models of the
disease, are likely the key responses associated with diabetic peripheral
neuropathy.
The second study further investigated a single high dose streptozotocin
model of type 1 diabetes mellitus by comparing tissues related to diabetic
peripheral neuropathy (sciatic nerve and dorsal root ganglia) and diabetic
nephropathy (renal glomerulus and cortex). RNA-sequencing identified
differentially expressed genes in each complication-prone tissue between healthy
controls and streptozotocin-treated mice. Genes with a conserved directional
change were analyzed using network and pathway analysis. Clusters related to
DNA-damage response, oxidative stress, and immune response were
represented in shared genes between diabetic nephropathy and diabetic
peripheral neuropathy tissue experiencing a common directional change. These
cluster themes are likely key conserved disruptions in microvascular
complication-prone tissue.
xvi

The third study explored neuroinflammation of the central nervous system
utilizing mice overexpressing α-synuclein under the mouse thymidine1 promoter
as an animal model of Parkinson’s disease. This murine model exhibits
parkinsonian motor and non-motor symptoms as well as α-synuclein aggregation
pathology. Early activation of microglia, the resident innate immune cells of the
brain, and an inflammatory response can be measured in the brains of these
animals as early as one month of age. RNA and DNA were extracted from
microglia isolated from these animals at 3 and 13 months of age for RNAsequencing and reduced representation bisulfite sequencing, respectively. The
time points for tissue collection involve the beginning of motor symptoms at 3
months and 13 months is immediately prior to a loss of 40% of dopamine
signaling which occurs at 14 months of age. The overexpression of α-synucleininduced both genomic methylation and gene expression changes that are
indicative of an immunologically activated M1 state of microglia. Correlation
between gene expression and a change in methylation status were investigated
but only intronic CG rich sites held a significant correlation with observed gene
expression (r=-0.15, p=0.008). Profiling the changes induced by α-synuclein
provides valuable insight into the systems contributing to disease progression.
Overall, these results warrant further investigation into the role
inflammation plays on the progression of neurodegenerative diseases. Our wide
range of models and techniques lends strength to the notion of common immune
activation pathways induced by a variety of disease insults in both the central
and peripheral nervous systems.
xvii

CHAPTER I
INTRODUCTION
Preface
The topic of this dissertation is focused on bioinformatics analysis of
neurodegenerative conditions in the peripheral and central nervous system and
the possible contributions from interactions with the immune system.
Inflammation of the nervous tissue or neuroinflammation, has been associated
with many neurodegenerative conditions. However, the question of whether the
immune response contributes to the cause of the disease or is an effect of the
disease condition has not been determined. Elucidating the role
neuroinflammation has on neurodegeneration as a cause or accelerator of
disease progression would provide essential insight for understanding the
pathophysiology of these debilitating conditions.
For this dissertation, three studies were conducted examining the
transcriptome of both peripheral and central nervous tissue in neurodegenerative
conditions. The first study compares the transcriptome of nerve biopsies from
patients with diabetic peripheral neuropathy (DPN) to sciatic nerve tissue from
various animal models of diabetes at different stages of DPN. This study
attempts to uncover a possible shared mechanism of injury in DPN across
progression of disease, types of diabetes, and species in order to identify new
2

therapeutic targets to treat DPN. The second study addresses the question of
gene expression changes as a result of vascular complications by examining
common differentially expressed genes in both DPN and diabetic nephropathy in
an STZ model of Type 1 Diabetes Mellitus (T1DM). The third study provides the
jump from peripheral nervous system (PNS) into the central nervous system
(CNS) by examining methylation and gene expression changes in a prominent
type of immune cell of the brain, microglia, from an animal model of Parkinson’s
Disease.
Neuroinflammation
The concept of neuroinflammation is by definition inflammation of nervous
tissue often referring to the central nervous system (CNS). The CNS is
considered immunologically privileged since peripheral immune cells are blocked
by the blood-brain barrier (BBB). The BBB is composed of astrocytes, pericytes,
and endothelial cells. The CNS has resident immune cells that play roles in
homeostasis and tissue repair as well as protect from infection. These cells
include microglia, astrocytes, and oligodendricites. Pio del Rio Hortaga was the
first to distinguish between microglia, oligodendrocytes, and astrocytes in the
central nervous system1–3. The inflammatory response is often initiated by
microglia which become activated by sensing pathogen or damage-associated
molecular patterns (PAMPs and DAMPs). Microglia then excrete cytokines and
chemokines which activate astrocytes and recruit other microglia. Not only can
this form a pro-inflammatory feedback loop between glia, but cytokines such as
TNF-α, IL-1β, IL-1α, C1q, and IL-6 may directly induce apoptosis in resident
2

neurons and oligodendrocytes4–8. In most cases this inflammatory state is
resolved naturally once the infection has been removed or tissue damage
repaired. Sustained inflammation suggests either a persistent stimulus or a
failure in resolution and may result in production of neurotoxic factors amplifying
disease conditions. This sustained inflammation has been implicated in multiple
neurodegenerative diseases, including but not limited to, Alzheimer’s Disease
(AD), Parkinson’s Disease (PD), multiple sclerosis (MS), and amyotrophic lateral
sclerosis (ALS)9–12.
Cellular Response to Inflammation in the CNS
Rudolf Virchow first proposed the idea of neuroglia in 1856; however,
Robert Remak is widely thought to be the first to include images of glia structures
in his figures as far back as 183813. Microglia are a type of glia cell that form the
front line of defense as resident macrophages of the innate immune system in
the brain and spinal cord. Microglia hold an essential role in the maintenance and
homeostasis of tissue as well as their role in response to infection and injury. In a
resting state, microglia exhibit a deactivated phenotype and produce antiinflammatory cytokines and neurotrophic factors14. Microglia switch to an
activated state in response to cellular injury or recognition of foreign material and
in such cases, produce pro-inflammatory cytokines to induce an inflammatory
response. Activated microglia recruit astrocyte’s participation in the inflammatory
response by secreting IL-1α, TNFα, and C1q, which together induce reactive
astrocytes15.

3

Astrocytes often present a star-shape with many processes extending
from the cell body and are commonly identified by their expression of glial
fibrillary acidic protein (GFAP)16. These cells are involved in a wide variety of
brain functions such as BBB maintenance, axon guidance during development,
provisioning of nutrients, and the repair process in response to injury or
inflammation17. The role of astrocytes in CNS regeneration are not well
understood, but upon injury, they will fill the space to form a glial scar, which is
required for regeneration to occur18. However, reactive astrocytes during
inflammation lose their neuroprotective status and instead induce death in both
oligodendrocytes and neurons15.
Oligodendrocytes surround the axons of neurons with their processes
similar to a Schwann cell in the PNS. Their main function is to insulate and
support axons by creating the myelin sheath which increases impulse speed and
decreases ion leakage19. Oligodendrocytes also contribute to the local cell
environment by producing glial cell line-derived neurotrophic factor (GDNF),
brain-derived neurotrophic factor (BDNF), and insulin-like growth factor (IGF-1).
However, these cells still play an active role during inflammation by secreting
cytokines as well as communicating with other glial cells20,21. These cells are
vulnerable to an inflammatory environment, which can lead to apoptosis of
oligodendrocytes affecting myelination of neurons as well as the cellular
microenvironment21.
Neurons are electrically excitable cells that receive, process, and transmit
information using electrical and chemical signals transmitted through specialized
4

connections called synapses. The communication between neurons is how all
information in the CNS is processed, including motor, sensory, and cognitive
information. This communication can be either electrical neurotransmission,
between two neurons at the electrical synapse, or chemical neurotransmission,
where neurotransmitters cross the synaptic cleft between neurons and act as a
chemical messenger22. An inflammatory environment can disrupt plasticity and
excitability in neurons and interfere with endoplasmic reticulum stress pathways.
Cell recruitment through inflammation has been shown to increase the
progression of neurodegenerative diseases. In PD multiple inflammatory
mediators such as reactive oxygen species, nitrous oxide, tumor necrosis factorα, and interleukin-1β, have all been shown to modulate the progression of
dopaminergic cell loss23,24. Further evidence supporting the role an inflammatory
response can have in PD is the lipopolysaccharide (LPS)-induced model of PD,
which displays dopaminergic neurodegeneration25.
Parkinson’s Disease
Parkinson’s Disease (PD) is the second most common neurodegenerative
disease appearing in nearly 1% of the population over 50 years old26. James
Parkinson first described what would become known as Parkinson’s Disease in
his Essay on the Shaking Palsy back in 181727. PD is a neurodegenerative
condition demonstrating intraneuronal protein aggregates referred to as Lewy
bodies and early death of dopaminergic neurons in the substantia nigra which
leads to a dopamine deficiency in the basal ganglia28. This deficiency leads to a
movement disordered characteristic of PD with tremors, bradykinesia, rigidity,
5

and postural instability29. The onset of these symptoms is typically not apparent
until approximately 80% of dopamine has been depleted and 60% of
dopaminergic neurons in the substantia nigra are already lost30–32. Non-motor
symptoms are also recognized with PD such as executive dysfunction, increased
risk of dementia, difficulty with impulse control, hallucinations, depression, and
anxiety33. PD is diagnosed based on medical history, signs and symptoms, and a
neurological examination while successful improvements under medication often
confirm the diagnosis34.
Lewy bodies (LBs) are not only associated with PD but can also be seen
in patients with dementia with LBs, multiple systems atrophy, and some other
disorders35. These protein aggregates are composed of α-synuclein, ubiquitin,
neurofilament, alpha B crystalline, and sometimes Tau36. LBs are mainly thought
to be in dopaminergic neurons in the substantia nigra of PD patients. However, at
late stages of disease they can also be found in noradrenergic, serotonergic, and
cholinergic systems as well as the cerebral cortex, olfactory bulb, and autonomic
nervous system37. The role LBs have in PD is not fully understood. They have
served as prediction sites for neuronal loss and proposed as a major correlative
factor in cognitive impairment38. However, recent studies have also suggested
that the fibrillary aggregates may be protective against the toxic oligomer and
protofibril forms of α-synuclein39–41.
Treatments and Proposed Causes
Treatments for PD aim to replace the loss of dopamine. Carbidopalevodopa is the most commonly prescribed treatment. Levodopa provides the
6

dopamine precursor so that more dopamine may be produced while carbidopa
inhibits the peripheral metabolism of levodopa so that it may be delivered to the
brain42. This is often given with an inhibitor to monoamine oxidase B (MAOB) and
catechol O-methyltransferase (COMT) to slow the metabolism of active
dopamine. Dopamine agonists have also been used to treat the symptoms of PD
and while they often aren’t as effective as levodopa they may last longer and
help to reduce the on-off effect of levodopa33. Deep brain stimulation has been
an effective surgical treatment providing advanced stage patients with sustained
benefit43. Non-motor symptoms are also targeted by pharmacological agents
used for their associated symptoms, such as erectile dysfunction being treated
with sildenafil citrate or isosmotic macrogol treating constipation44. Current
treatments involve targeting symptoms of PD rather than slowing or stopping the
progression of the disease since the cause and contributing factors are not well
defined.
The current hypotheses concerning causative factors in PD revolve
around environmental toxins, genetic factors, and oxidative stress. The
environmental hypothesis proposes that exposure to dopaminergic neurotoxins
lead to PD related neurodegeneration. This began when it was found that people
using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) develop a condition
very similar to PD45. Other insecticides and herbicides such as rotenone or
paraquat can also act as a dopaminergic neurotoxin46,47. This review outlines
studies that have shown living in a rural environment with greater exposure to
these chemicals increases the risk for developing PD48. Environmental factors
7

that play a protective role from PD have also been identified such as smoking
cigarettes, drinking coffee, non-steroidal anti-inflammatory drug use, and use of
calcium channel blockers49,50. While exposure to various environmental factors
modify susceptibility to PD, genetic mutations or familial forms of the disease
have also been observed51–57.
The first gene associated with autosomal dominant PD was alphasynuclein (SNCA) in 199751, which encodes the α-synuclein protein found
aggregated within LBs. The most common risk factor mutations involve leucinerich repeat kinase (LRRK) and parkin (PRKN) genes, while the greatest genetic
risk for developing PD are mutations to the GBA gene, encoding βglucocerebrosidase52,53. Overall, multiple genetic association studies have been
conducted in PD and over 24 loci have been identified as increasing the risk
factor of developing PD41,58–60. Genetic mutations in SNCA have also been
shown to modify environmental risk factors affecting the risk for PD development
associated with head injury54. Interestingly, multiple PD associated genes are
involved in the ubiquitin-proteasome pathway55. While inherited or familial forms
of PD are not as common as the idiopathic form, the discovery of PD-associated
genes has been critical to PD research through the development of animal
models of the disease widely used in research today52,53. Overall, studies in both
toxin and inherited forms of PD suggest mechanisms that contribute to the loss of
dopaminergic neurons such as misfolding and aggregation of proteins,
mitochondrial dysfunction and associated oxidative stress, including oxidized
dopamine species36,56,57.
8

Animal Models of Parkinson’s Disease
Many studies examining PD have used chemically induced models of the
disease including MPTP61, rotenone62, paraquat46,47, amphetamine model63, and
6-OHDA64. These neurotoxin models of PD are best used to test degeneration of
nigrostriatal dopaminergic neurons, but they often possess their own drawbacks
as well. Degeneration in these models usually progresses very quickly over a
couple days, while PD progression takes place over years in humans65. The
MPTP and 6-OHDA models do not present the characteristic LB formations in
neurons66–68. Both the rotenone and paraquat models have had high mortality
rates and variable cell death or loss of striatal dopamine69,70. Models using
methamphetamine (METH) or 3,4-methylenedioxymethamphetmaine (MDMA)
also demonstrate serotonergic toxicity and are often used in conjunction with
other toxins to influence the progression of symptoms71–75. The challenge of
inducing a PD phenotype into a mouse model has led to a variety of models that
demonstrate the death of dopaminergic neurons along with unique sets of
symptoms and abnormalities for each model.
Genetic models of PD are also often used to study familial forms of the
disease with the idea that similar phenotypic changes indicate common
mechanisms in the more common, sporadic form of PD. The most commonly
studied PD genes: α-synuclein, LRRK2, PINK1, PRKN, and Protein Deglycase
(DJ-1) can all be linked to the ubiquitin-proteasome pathway30. The most
fundamental drawback to many of these disease models is that they do not
demonstrate a significant loss of dopaminergic neurons76–79. The knockout (KO)
9

mice for PINK1, PRKN, and DJ-1 all have similar phenotypes with decreased
locomotor activity and slightly decreased dopamine levels but without loss of
dopaminergic neurons80–85. LRRK2-mutated mice typically experience mild
disruption of nigrostriatal dopaminergic neurons without neuropathological
symptoms, but they do display α-synuclein or ubiquitin accumulation77,86–88.
There are many different α-synuclein transgenic models. While some have
behavioral impairments and lowered dopamine levels, there is usually not a
significant amount of neurodegeneration89–92. Overexpression models of αsynuclein can display neurodegeneration and behavioral alterations depending
on the promoter used93,94.
The mouse thymidine 1 promoter (m-Thy1) is used to drive
overexpression of full-length human wild-type α-synuclein in the C57B16/DBA2
background mouse as a PD model95. This model shows progressive changes in
both motor and non-motor symptoms, striatal dopamine levels, α-synuclein
pathology, and inflammation typically observed in PD96. These mice overexpress
the α-synuclein protein at 1.5-3.4 fold higher than wild-type littermates in most
regions of the brain, which is similar to levels observed in patients with gene
triplication of α-synuclein associated with a familial form of PD96. These mice
rapidly lose 40% of striatal dopamine between 12 and 14 months of age, but
there is no reduction in the amount dopaminergic neurons97. At 14 months, this
model also fails many motor tests such as decreased locomotion and slowness
in sensory motor tests without motor neuron pathology. These deficits can both
be reversed with levodopa treatment, suggesting they are more reflective of
10

human PD95,97–99. This model also shows early innate inflammation in the brain
and late peripheral inflammation similar to PD patients100–102. Microglia can be
found activated in the striatum as early as 1 month and in the substantia nigra at
5-6 months along with increased tumor necrosis factor-α100,103. One PD hallmark
this model does not demonstrate is the loss of dopaminergic neurons; however, a
progressive process of terminal loss has been observed, which suggests this
system as a model of early stages of PD prior to neuronal cell death104.
Peripheral Inflammation
Inflammation is the body’s response to pathogens, damaged cells, and
irritants. This process utilizes immune cells and molecular mediators to eliminate
the cause of cell injury or clear out damaged cells/tissue and initiate tissue repair.
When microorganisms invade the body they are usually destroyed by lysozymes
or phagocytosis with intracellular digestion as the typical mechanisms of the
innate immune system105. The first component of the innate immune system
encountered by a pathogen after breaching the body is generally neutrophils and
residential cells trying to neutralize intruders by either ingestion by phagocytosis,
degranulation with anti-microbials, or by trapping with neutrophil extracellular
traps (NETs)106. This is closely followed by a response of the complement
system107 as a collection of proteins in bodily fluid, which coat the pathogen in
complement proteins to assist phagocytic cells108,109. The cells involved in the
innate immune system consist of macrophages, dendritic cells, mast cells, innate
lymphoid cells, neutrophils, natural killer cells, basophils, and eosinophils107.
Natural killer cells and eosinophils are responsible for destroying host cells
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infected by a virus or parasite110. Macrophages, dendritic cells, mast cells, and
neutrophils are all characterized as phagocytes which protect the body by
ingesting foreign particles, bacteria, and dead cells. Phagocytes have specialized
receptors on their surface called pattern recognition receptors (PRRs) to detect
harmful objects not normally found in the body making them critical for fighting
infection and maintaining healthy tissue111.
PRRs are germline-encoded host sensors that identify PAMPs, such as
microbial pathogens, or DAMPs which are endogenous stress signals112. These
receptors can be grouped into toll-like receptors (TLRs), c-type lectin receptors
(CLRs), NOD-like receptors (NLRs), and RIG-I-like receptors (RLRs)113. The
resultant signaling from these various families of receptors interact in a complex
system to promote the appropriate immune response to neutralize the current
inflammatory stimulus. Often, multiple families of PRRs are activated at the same
time with signaling pathways that can be both inhibitory and facilitatory to each
other resulting in a dynamic system of regulation to engage immune activation at
a cellular level114.
If the innate immune system is unable to clear the inflammatory stimulus
after four to seven days then the adaptive immune response may be activated115.
The adaptive immune response is a learned response to a specific pathogen that
offers long term protection. The cells that carry out the adaptive immune
response are B cells and T cells. Plasma cells (fully differentiated B cells) secrete
antibodies, while T cells control intracellular infections by playing various roles in
the inflammatory response. T cells can secret mediators to activate other cells
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and enhance defense mechanisms such as when T helper cells activate B cells
in the presence of antigens116. T cells can also become a cytotoxic type of T cell
which kill the target organism117.
Communication and recruitment of both adaptive and innate immune cells
is conducted using small soluble molecules called cytokines including
chemokines, interleukins, growth factors, and interferons. These proteins
regulate the amplitude and duration of the immune response and require tight
regulation, since they can be highly active at low concentrations. The specific
action of each cytokine is dependent on the stimulus, cell type and other
mediators and receptors. For example, cytokines can serve as a means of
communication between the peripheral nervous system and immune system by
increasing membrane excitability in nociceptor neurons118–120. In chronic
inflammatory cases, it is not uncommon for tissue and cellular death to occur as
a result of cytotoxic defense mechanisms of the immune system121–123. Antiinflammatory cytokines play a crucial role in limiting these potentially dangerous
inflammatory effects124. Successful resolution of the inflammatory process relies
on shifting the balance of pro and anti-inflammatory cytokines toward antiinflammatory expression.
Diabetic Peripheral Neuropathy
Diabetes mellitus or, diabetes, is a metabolic disorder, in which blood
sugar control is lost due to either a lack of insulin or the body becoming insulin
insensitive. There are three types of diabetes with type 1 diabetes mellitus
(T1DM) being associated with an insulin deficit due to a loss of pancreatic beta
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cells125. Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance
usually associated with obesity. Type 3 is termed gestational diabetes, occurring
in women during pregnancy. This family of conditions is associate with acute
complications such as ketoacidosis, hyperosmolar hyperglycemic state, and
death as well as long-term complications including nephropathy, retinopathy,
cardiovascular disease, and neuropathy126. Diabetic peripheral neuropathy
(DPN) is the most common complication of diabetes, presenting with numbness,
tingling, and pain in the extremities127. This, in conjunction with damaged blood
vessels, can lead to skin damage, which is associated with diabetic foot ulcers as
well as muscle atrophy and weakness128.
Current treatments for DPN are limited to tight blood glucose control and
pain management. Most common medications prescribed include
anticonvulsants, antidepressants, and opioids to help manage pain. Glucose
control is significantly more effective as a treatment for patients with DPN in
T1DM than T2DM129,130. This leaves the majority of patients with DPN resigned to
pain medication.
The major mechanisms thought to influence DPN involve hyperglycemia,
dyslipidemia, and disrupted insulin signaling. Hyperglycemia leads to increased
oxidative stress through increase flux pathway activity and overwhelming the
electron transport chain to generate reactive oxygen species (ROS)131–133.
Chronically high blood sugar can also increase production of advanced glycation
end products (AGEs) that bind extracellularly to the receptor for AGE (RAGE),
which initiates an NF-kB inflammatory pathway and generates ROS134–136.
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Dyslipidemia, which is thought to be critical in T2DM, has been linked to DPN
progression through high levels of free fatty acids (FFAs), oxysterols, low-density
lipoproteins (LDLs)137. FFAs have been shown to directly injure Schwann cells
and promote proinflammatory cytokine release from surrounding immune cells.
LDLs modified by either oxidization or glycation can bind to toll-like receptor
(TLR) and RAGE136,138,139. The insulin resistance (T2DM) or deficiency (T1DM)
that disrupts normal insulin signaling increases mitochondrial stress within
neurons140. There is some evidence that insulin can may have a neurotrophic
effect which is lost in diabetes. Removing the native neurotrophic effect that
insulin has on neurons may also contribute to DPN progression141. All of these
mechanisms result in various cell stress processes creating a damaging
environment for all resident cells. This can trigger the recruitment of
macrophages engaging a feedback loop of inflammatory cell stress and death
with a persistent stimulus related to the diabetes phenotype142,143. The insight
into these contributing mechanisms has largely been obtained through the study
of multiple animal models of diabetes used in scientific studies.
Animal Models of Diabetic Peripheral Neuropathy
Several animal models of diabetes have been developed for both T1DM
and T2DM, which demonstrate varying levels of DPN. While the models that
have been developed demonstrate a diabetic phenotype along with mild
neuropathy, they do not reflect the severity of the human disease144–146. This
dissertation contains studies utilizing the single high dose (SHD) streptozotocin
(STZ), leptin receptor mutated (db/db), and leptin knockout (ob/ob), which we will
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focus on while discussing some advantages and disadvantages for these and
alternative models.
The mouse models of T1DM are either chemically induced using STZ or
genetic models of the disease. The chemically induced model utilizes STZ to
target the pancreatic β cells where it interferes with glucose transport and
induces DNA double strand breaks147,148. Two different dosing regiments of STZ
are commonly used to induce β cell death in this model, either a SHD or multiple
low doses (MLD). The changes in dosing assist with the severe toxicity and post
injection mortality observed in the SHD, but the MLD model will often show
moderate to no signs of neuropathy dependent on the strain. The genetic models
of T1DM include the non-obese diabetic (NOD) and B6Ins2Akita mice. NOD mice
have an immunodeficiency similar to that seen in humans with T1DM149. NOD
mice experience the onset of diabetes around 12 to 14 weeks150,151, but very little
neuropathy characterization has been done in this model besides the observation
of hyperalgesia at 8 weeks and hypoalgesia at 12 weeks152,153. The B6Ins2Akita is
induced through a point mutation in the Ins2 insulin gene which impairs insulin
secretion and results in hyperglycemia154. This model demonstrates a diabetic
phenotype by 7 weeks of age and neuropathy around 16 weeks of age155.
However, there has been some conflicting studies suggesting that there were no
significant impairments in nerve conduction velocities at 24 weeks of age156.
While further characterization of DPN in the B6Ins2Akita model is required, their
ability to respond to insulin treatments is unique157.
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Models of T2DM are either genetic or diet-induced and here we will focus
on models characterized with a neuropathy phenotype158. Genetic models were
generated by identifying a spontaneous mutations disrupting leptin signaling
through either a leptin receptor mutation (db/db159) or leptin knockout (ob/ob160).
The db/db mouse develops diabetes at 4 weeks, hyperalgesia at 8 weeks, then
allodynia and hypoalgesia after 12 weeks144,161–163. This along with deficits in
motor and sensory nerve conduction velocities make the db/db mouse a robust
model of DPN. However, there is some strain variability with the C57BL/6 mice
only having limited or no neuropathy while C57BKS mice have a robust
phenotype144,158,163,164. The ob/ob mouse is not as well studied in DPN, but as a
model of mild T2DM, decreased neuron conduction velocity can be observed at
11 weeks of age along with other measurements of neuropathy165.
Diet-induced models involve a high-fat diet (HFD), which will develop dietinduced obesity in the mice through a gradual onset of metabolic imbalances
characteristic of human T2DM138,166–168. This model also allows a unique
examination of prediabetes which has been shown to be a contributing factor to
neuropathy in nondiabetic patients169. These obese HFD mice do not
demonstrate elevated glucose levels and never fully develop diabetes, although
other phenotypic changes have been observed168. The hallmarks of DPN have
been observed after 16 weeks of age in HFD mice characterized as
prediabetic170. Strain variability has also been observed in this model with
different amounts of vulnerability to diet-induced obesity, but most DPN studies
have been conducted using the C57/BL6 background171. One unique feature of
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this model is the ability to observe DPN reversal by switching HFD mice back to
a standard diet168. This finding could allow further insight into restorative
mechanisms.
Dissertation Research Objective
The objective of this dissertation is to characterize transcription signatures
associated with central and peripheral inflammation, with an emphasis on
Parkinson’s disease and diabetic peripheral neuropathy. Our wide range of
models and techniques lends strength to the notion of common immune
activation pathways induced by a variety of disease insults.
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CHAPTER II
CONSERVED TRANSCRIPTIONAL SIGNATURES IN HUMAN AND MURINE
DIABETIC PERIPHERAL NEUROPATHY
Abstract
Diabetic peripheral neuropathy (DPN) is one of the most common
complications of diabetes. In this study, we employed a systems biology
approach to identify DPN-related transcriptional pathways conserved across
human and various murine models. Eight microarray datasets on peripheral
nerve samples from murine models of type 1 (streptozotocin-treated) and type 2
(db/db and ob/ob) diabetes of various ages and human subjects with nonprogressive and progressive DPN were collected. Differentially expressed genes
(DEGs) were identified between non-diabetic and diabetic samples in murine
models, and non-progressive and progressive human samples using a unified
analysis pipeline. A transcriptional network for each DEG set was constructed
based on literature-derived gene-gene interaction information. Seven pairwise
human-vs-murine comparisons using a network-comparison program resulted in
shared sub-networks including 46 to 396 genes, which were further merged into
a single network of 688 genes. Pathway and centrality analyses revealed highly
connected genes and pathways including LXR/RXR activation, adipogenesis,
glucocorticoid receptor signaling, and multiple cytokine and chemokine
pathways. Our systems biology approach identified highly conserved pathways
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across human and murine models that are likely to play a role in DPN
pathogenesis and provide new possible mechanism-based targets for DPN
therapy.
Introduction
According to the United States Centres for Disease Control and
Prevention (CDC), more than 29 million Americans, over 9% of the United States
population, are living with diabetes and another 86 million have prediabetes172.
The most common microvascular complication of diabetes is diabetic peripheral
neuropathy (DPN) which occurs in approximately 60% of patients and is the
leading cause of non-traumatic lower-limb amputations173,174. DPN is
characterized by distal to proximal degeneration of peripheral nerves which
results in symptoms such as numbness, pain, and weakness175. Other than
glucose control, there are no disease-modifying treatments for DPN.
Understanding DPN pathology and identifying the underlying mechanisms of
peripheral nerve degeneration are therefore critical to the development of new
mechanism-based therapies for DPN.
Over the past decade with the advent of high-throughput gene expression
profiling assays such as microarrays and RNA-Seq, we and others have
examined genome-wide gene expression changes from the peripheral nerve
tissues of various diabetic murine models176–180 and human subjects181,182 with
diabetes. Bioinformatics analyses of these high-throughput datasets identified
numerous genes in human and murine peripheral nerves that are significantly
dysregulated by diabetes. Suggested mechanisms of injury such as
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inflammation, oxidative stress, lipid and carbohydrate metabolism, regulation of
axonogenesis, mitochondrion, and peroxisome proliferator-activated receptor
(PPAR) signaling were also reported during diabetes onset and
progression177,178,180,181.
Yet, one limitation of the previous studies, including ours, is that the
analyses didn’t account for the differences in species, strains, procedure of
diabetes induction, and diabetes duration. Another critical issue that hasn’t been
addressed thus far is the identification of common injurious pathways and
networks conserved across various mouse models of diabetes as well as
between mouse and human. In this study, we reanalyzed previously published
DPN-related microarray datasets from human and multiple murine models using
a unified analysis pipeline. Compared with the existing literature, this study
provides a unique opportunity to uncover a possible common mechanism of
injury shared across DPN stages, types of diabetes, and species. Such
mechanisms could unravel new important therapeutic targets to treat DPN.
Research Design and Methods
Microarray Data
All datasets used were gathered from the University of Michigan Diabetic
Neuropathy Microarray Knowledge-Base (DNMKB;
http://hurlab.med.und.edu/DNMKB/). The data from the type 1 diabetes mellitus
(T1DM) model were originally generated from male DBA/2J mice treated with
streptozotocin (STZ) at 10 weeks that were terminated at 34 weeks180. The two
type 2 diabetes mellitus (T2DM) models included BKS.Cg-Leprdb/db (db/db) mice
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and BTBR.Cg-Lepob/ob (ob/ob) mice. The male db/db mice were 8, 16, and 24
weeks176,178,183, while male ob/ob mice were 5 and 13 weeks of age177. A female
ob/ob dataset was also available from 26 weeks old BTBR.Cg-Lepob/ob mice184.
Each dataset was originally generated using sciatic nerve samples on the
Affymetrix Mouse Genome 430 2.0 array platform. As previously reported each
model displayed the features typical of diabetes by the termination of their
respective studies as well as the hallmarks of DPN176,177,184. The human sural
nerve data used was generated using the Affymetrix Human Genome U133 Plus
2.0 array platform178. As previously reported these samples were evaluated for
features of DPN and were separated into progressive and non-progressive
groups based on the myelinated fibre density lost over a 52 week period178.
Study Design
Figure 1 illustrates the overall workflow of the current study, designed to
reanalyse these microarray data from sciatic nerve (SCN) samples taken from
our T1DM and T2DM murine models when compared to controls and the human
microarray data from sural nerve biopsies, from patients with progressive and
non-progressive DPN. The original datasets were separated into these groups
(either diabetic vs healthy or progressive vs non-progressive) and were
compared using ChipInspector (Genomatix Software GMBH,
http://www.genomatix.de) to identify the differentially expressed genes (DEGs)
between groups. The DEG lists identified from each murine model were
converted to the human orthologue equivalent when possible using the
Genomatix annotation orthologue database. These DEG lists of human gene IDs
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were then compared across datasets to identify the conserved DEGs between
the different murine models and human. Each DEG set was also analyzed using
Ingenuity Pathway Analysis (IPA; http://www.ingenuity.com) from Qiagen (Hilden,
Germany) and the identified pathways were compared across models and
species to identify the commonly disrupted pathways. To identify gene networks
common between models, networks were generated from these DEG datasets
using SciMiner185. The networks generated were analyzed for common network
nodes and disrupted pathways using IPA.
Transcriptome Profiling
Transcriptomic data generated from Affymetrix GeneChips were analyzed
using BioConductor (https://www.bioconductor.org/) and their Affymetrix QC
packing in R (http://www.arrayanalysis.org/). All data passing our quality
threshold were then analyzed using ChipInspector and up-to-date gene
annotation. Expression signals from the microarray image files were analyzed at
the single probe level. Significant transcripts were defined using a minimum of
five significant probes and a false discovery rate of <1% by the Significance
Analysis of Microarrays algorithm using exhaustive comparisons between control
and diabetic mice. Eight datasets of DEGs were generated based on significant
transcripts between control and diabetic groups for each murine model (8, 16,
and 24 week db/db; 5, 13, 26 week ob/ob; and 34 week STZ) as well as between
progressive and non-progressive groups for the human dataset176–178,180,181,183,184.
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Figure 1. Model and Network DEG Comparison Workflow. Previously
published microarray datasets were reanalyzed using ChipInspector to identify
DEGs at various time points from murine models of type 1 diabetes (STZ), type 2
diabetes (db/db and ob/ob), and human patients. DEG datasets from all murine
models were generated by comparing diabetic to healthy control mice. The
human samples were grouped into progressive and non-progressive groups to
determine the DEG dataset used. All DEG datasets were compared in order to
find the DEGs shared across models and stages of DPN. These shared DEGs
were analyzed using IPA to identify possible disrupted signaling pathways.
Seven pairwise comparisons were performed to determine the shared networks
between each murine dataset with our human dataset. These DEGs were then
analyzed using IPA to identify possible disrupted signaling pathways.
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Diabetes- and Age- Comparisons of DEGs Sets
The eight DEG sets were compared to find shared DEGs between
species, stages of neuropathy, and diabetes type at a gene and network level.
Each dataset was assessed in previous publications for characteristics of DPN
and defined as a specific stage of DPN176–178,180,183,184. All DEG sets were
examined for overlap to identify the conserved pathways or genes responsible for
the underlying cause of DPN in the different murine and human samples.
Transcriptional Network Comparison
Each DEG set was used to generate transcriptional networks based on
gene-gene associations that were identified from biomedical literature using
SciMiner185. SciMiner is our in-house literature mining system that analyses over
24 million abstracts in PubMed to automatically extract potential gene-gene
interactions based on their co-occurrence at the sentence level. The network for
each of the eight DEG sets were constructed individually following mouse gene
to human gene orthologue conversion according to the Geomatics annotation
orthologue database. Cytoscape version 3.3.0 (http://www.cytoscape.org)186, an
open-source platform for visualizing complex networks, was used to visualize
SciMiner-generated transcriptional networks.
Each mouse DEG network was compared to the human DEG network in a
pairwise manner, using a Tool for Approximate Subgraph Matching of Large
Queries Efficiently (TALE)187. TALE compares network structure and extracts
overlapping conserved relationships between two networks. The mismatch
parameter used allows 10% mismatch when generating seed gene nodes and
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extended networks as in our previous studies188,189. Conserved nodes across
networks were then examined and analyzed for overlapping pathways using IPA.
Functional Enrichment Analysis
IPA was used to identify enriched pathways within each of the eight DEG
sets as well as the seven TALE generated network comparison datasets
(comparing each mouse DEG set to our human DEG set). These pathways for
the eight DEG sets were compared to identify conserved disrupted pathways that
may indicate an underlying cause to DPN. The disrupted pathways observed in
our TALE datasets were also compared in order to identify a possible central
pathway based on nodes and subnetworks generated from our transcriptional
network comparison. The background list of genes used for this analysis was the
Affymetrix Human Genome U133 Plus 2.0 Array.
Construction of Merged Human-Mouse-Conserved Transcriptional
Network and Network Centrality Analysis
Eight TALE networks were combined using the merge function in
Cytoscape. Edges supported by less than three citations according to SciMiner
were removed from the network. The merged human-mouse-conserved
transcriptional network was examined to identify the most central genes in the
network. Using package ‘sna’, tools for social network analysis, in R
(https://CRAN.R-project.org/package=sna), four centrality metrics (degree,
eigenvector, closeness, and betweenness) were computed to identify the most
important nodes (i.e., genes) in the merged transcriptional network. These four
different centrality metrics measures different aspects of node
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characteristics190,191.
Briefly, the degree centrality is the number of nodes that are its first
neighbors (i.e., directly connected to the given node). The more connections a
node has, the more central it is, based on degree centrality. In eigenvector
centrality, a node contributes to the centrality of another node proportionally to its
own centrality. A node is more central, if it is connected to many central nodes.
The other two metrics (closeness and betweenness) is dependent on the position
of a node in the network. Closeness centrality is based on the distance of a node
to the other nodes in the network. The closer a node is to the other nodes, the
more important it is considered to be. Betweenness centrality is based on the
number of shortest paths connecting two nodes that pass over the given node. A
node is more central, if it acts like a bridge in the network, i.e., lies on many
shortest paths. In the current study, we defined the top 10 or 50 most central
genes, belonging to the ranks of the genes using each metric. These gene sets
were further examined for their enriched biological functions using IPA.
The validity of the central genes was examined by comparing against the
average centrality scores from randomly generated transcriptional networks. We
generated 1,000 gene sets for each of the eight DEG sets containing the same
number of genes randomly selected from all the genes available on the
microarray platform. These random gene sets were processed in the same exact
way as the real data sets, which resulted in 1,000 merged shared networks. The
four centrality scores were measured for each gene in the networks and were
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used as the background distribution for a Z-test of the centrality scores from the
real data.
Results
Identification of Changes in Gene Expression
Gene expression profiles were generated using eight published datasets
from sciatic nerve samples from both T1DM and T2DM murine models with DPN
as well as human sural nerves from patients with T1DM and T2DM176–
178,180,181,183,184

. Metabolic and neuropathy phenotyping on all animal models as

well as human subjects are summarized in Table 1 based on the published
reports. Briefly, T2DM mouse models (ob/ob and db/db) were significantly
heavier and displayed higher levels of fasting glucose levels and glycosylated
hemoglobin, when compared with age-matched non-diabetic controls (ob/+ and
db/+, respectively). Triglyceride levels were significantly increased in T2DM mice.
STZ-induced T1DM mice had significantly reduced body weight and higher
fasting blood glucose and glycosylated hemoglobin levels relative to non-diabetic
controls. Motor and sensory nerve conduction velocities (NCVs) were
significantly lower in diabetic mice at all stages of diabetes. Intra-epidermal nerve
fiber density (IENFD) was significantly decreased in ob/ob mice at 9 and 13
weeks compared with age-matched control littermates. Similar changes were
observed in the db/db mouse model at 16 and 24 weeks of age. Both IENFD loss
and reduced NCVs confirm the development of DPN in murine models of
disease192. In the human subjects, there was a change in myelin fibre density
(MFD) over the course of the 52-week study between subjects with progressive
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versus non-progressive neuropathy181. However, other factors, including gender,
age, insulin treatment, triglyceride levels, glycosylated hemoglobin and body
mass index (BMI), were not significantly different between the two groups.
ChipInspector was used to reanalyze each dataset and identified between
438 – 5,757 DEGs within each dataset (Table 2). Gene expression profiles were
based on a healthy control vs DPN comparison for each murine model while the
human sural nerve comparison was based on comparing patients with
progressive versus non-progressive DPN181. Across all eight datasets, over
11,000 genes were identified with at least 2,100 being shared across at least 3
datasets. Most murine models displayed a similar expression pattern while our
T1DM model (STZ-treated) showed a distinct pattern (Figure 2). Some of the
most common genes identified across these models include interleukin 1
receptor antagonist (IL1RN)193,194, complement component 3a receptor 1
(C3AR1), macrophage scavenger receptor 1 (MSR1)195,196, and matrix
metallopeptidase 12 (MMP12)197, which have been implicated in the
pathogenesis of DPN. Table 3 illustrates the enrichment levels of the most
frequently enriched pathways identified in at least five DEG sets in these
datasets by IPA. These pathways include many genes related to lipid
metabolism, extracellular matrix homeostasis, and immune signaling, which have
all been implicated in the pathogenesis of DPN177,178,180,182–184,188,198,199.

29

Published Datasets Included

db/db
183

8 wks (M)

db/db
16 wks

db/db
24 wks

178

176

(M)

(M)

ob/ob
177

5 wks (M)

ob/ob
13 wks
177

(M)

ob/ob
26 wks
184

(F)

DBA2J-STZ
34 wks
180

(M)

Human
DPN

181

Metabolic measures

Fasting glucose

↑
↑

Triglycerides

N/A

% Glycosylated hemoglobin

↑

Body weight

↑
↑
↑
↑

↑
↑
↑
↑

↑
↑
↑
↑

↑
↑
↑
↑

↑

↓
↑

BMI: N/S

↑
↑

N/A

N/S

↑

N/S

↑
↓
↓

N/A

N/A

N/A

Neuropathy phenotype measures

↑
↓
↓
↓

↑*
↓*
↓*
↓*

N/A

N/A

N/S

↑
↓
↓
↓

↓
↓
↓

↓
↓
↓

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

↓

Hindpaw latency

N/S

Motor nerve conduction velocity
Sensory nerve conduction velocity

↓
↓

Intra-epidermal nerve fiber density
Myelinated fiber density changes over 52 wks

N/A
N/A

Table 1. Metabolic and neuropathy phenotypic measures of microarray datasets. The previously published datasets
included in this study have all been tested for measurements of metabolic disturbances and neuropathic phenotyping
independently. The increase (+) or decrease (-) indicates the changes observed in diabetic animals compared to their
respective non-diabetic controls and between the progressive and non-progressive human patients. Not all studies
underwent the same testing and measurements not included are indicated by an N/A, while non-significant results
(p>0.05) are indicated by N/S. The superscript numbers in the header row correspond to the reference numbers in the
manuscript. BMI: body mass index; M: male; F: female. wks: weeks. * indicates that measurements taken at 9 weeks in
the published study.
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Dataset
8wk db /db
16wk db /db
24wk db /db
5wk ob /ob
13wk ob /ob
Female 26wk
ob /ob
34wk DBA2JSTZ
Human sural
nerve

Number of
Control
Samples
6
6
6
8
6

Number of
Diabetic
Samples
5
6
6
8
6

DEGs identified
by
ChipInspector
2,955
871
5,068
2,096
723

5

5

482

4

5

3,022

17 nonprogressive

18
progressive

5,757

Table 2. Study 1 Dataset Summary. The number of samples for both control
and diabetic samples within each dataset is represented in the 2nd and 3rd
column. The human dataset rather than being healthy versus diabetic samples
were grouped into non-progressive and progressive groups based on myelin fibre
density lost. The amount of DEGs identified by ChipInspector ranged from 482 to
5,757 for each dataset.
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Figure 2. DEG patterns in study 1 DPN models. Over 11,000 genes were identified and at least 2,100 were shared
across a minimum of 3 datasets. This heat map shows the pattern of distribution for DEGs across models to display how
similar or different each model used in this analysis appeared to be on a transcription level.
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pathway
Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis
Clathrin-mediated Endocytosis Signaling
Hepatic Fibrosis / Hepatic Stellate Cell Activation
Growth Hormone Signaling
Atherosclerosis Signaling
LXR/RXR Activation
Axonal Guidance Signaling
Inhibition of Matrix Metalloproteases
Leukocyte Extravasation Signaling
Production of Nitric Oxide and Reactive Oxygen Species in Macrophages
Type II Diabetes Mellitus Signaling
PPARγ/RXRα Activation
Calcium Signaling
Glioma Invasiveness Signaling
Paxillin Signaling
Renin-Angiotensin Signaling
Aryl Hydrocarbon Receptor Signaling
Reelin Signaling in Neurons
Role of JAK1 and JAK3 in Î³c Cytokine Signaling
MSP-RON Signaling Pathway
Angiopoietin Signaling
ERK/MAPK Signaling
IL-8 Signaling

count 8wk_dbdb 16wk_dbdb 24wk_dbdb 5wk_obob 13wk_obob F26wk_obob 34wk DBA2J-STZ Human
7
7
6
6
6
6
6
6
6
6
6
5
5
5
5
5
5
5
5
5
5
5
5

3.32
2.72
3.42
2.48
2.15
1.33
3.27
1.58
1.74
1.59
1.44
1.50

2.45
2.05
6.24
1.46
2.17
5.79
1.57
1.30
1.82
1.53
2.50
1.73

4.15
1.59
1.38
2.73
2.43
1.73
1.35
2.06
1.64
5.19

1.92

1.61
1.93
2.01
2.41
2.06
3.02
2.12
2.28
1.34

3.50
3.90
8.70
2.23
11.50
7.11
3.62
3.36
4.95
6.53
1.80
3.85

2.43

1.63
1.46
2.57

2.22
1.36
3.32
1.83
2.91
2.01
1.53

1.75
2.19
1.55
3.14
1.99
3.83
4.44
3.00

2.05
1.87
1.95
1.68
5.05

2.04

3.22

1.42
2.27
1.97

1.32
1.95

1.99
2.08
2.08
2.15
4.30

1.78
2.26
2.30

4.98
1.53
3.09
1.32
5.67
4.63
2.59

1.95
2.12
1.55

5.76
2.91
1.75
2.15
1.68
1.60
1.42
1.61
3.10
1.50
2.55
1.86

2.65
2.29
2.26
2.19
2.04
1.67
1.65
1.62
1.37

1.79
2.22

Table 3. Most frequently dysregulated canonical pathways in study 1 datasets identified by Ingenuity Pathway
Analysis (IPA). Each dataset was analyzed using IPA for canonical pathway enrichment then compared to determine the
most frequently enriched pathways across datasets. The numbers and color gradient within the table are -log (p values) to
represent significant enrichment within each column.
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Transcriptional Network Analysis
Our network analysis refines the datasets by examining the connections
between identified DEGs to allow prioritization of possibly centrally influential
genes or pathways. Prior to pathway analysis with IPA, transcriptional networks
are generated based on gene-gene associations, among DEGs, that are
identified for each dataset using SciMiner185. These networks were then
compared in a pairwise manner between murine and human datasets using
TALE with a 10% mismatch parameter to limit the shared network187. Networks
ranging from 46 – 396 genes were identified as shared between each murine set
of DEGs and the progressive human set of DEGs (Table 4; Figure 3). The top
network DEGs identified as shared across datasets within the compared
networks are presented in Table 5. Among these shared DEGs there is a large
number of immune factor genes such as CD44, Interleukin 1 receptor antagonist,
and macrophage scavenger receptor 1.
Other notable genes identified in this shared network include dipeptidyl
peptidase 4 (DPP4), a serine peptidase that modulates the levels of incretin
hormones, major regulators of glucose homeostasis200. The antidiabetic action of
DPP4 inhibition has been associated with a partial amelioration of NCV deficit in
T1DM rats as well as a reduction in nerve fiber loss201,202. The identification of the
immune genes previously described as well as other target genes associated
with DPN suggests that our network approach can successfully narrow the focus
of transcriptomic data.
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Genes
Orthologue
included in
DEGs
Number of Number of
mapped
the literatureidentified by
diabetic
control
Human
derived
samples ChipInspector
samples
Gene IDs
network
6
5
2,955
2,782
2,194

Dataset

db/db 8 wks (M)183
db/db 16 wks (M)178
db/db 24 wks (M)176

6

6

871

794

579

6

6

5,068

4,743

3,762

ob/ob 5 wks (M)177
ob/ob 13 wks (M)177

8

8

2,096

1,910

1,535

6

6

723

685

509

ob/ob 26 wks (F)184

5

5

482

438

338

4

5

3,022

2,482

1,932

5,757

5,757

4,232

180

DBA2J-STZ 34 wks (M)
181

Human DPN

17 non18
progressive progressive

Table 4. Summary of the microarray datasets. The number of samples for both control and diabetic samples within
each dataset is represented in the 2nd and 3rd column. The human dataset rather than being healthy versus diabetic
samples were grouped into non-progressive and progressive groups based on myelin fiber density lost. The amount of
DEGs identified by ChipInspector ranged from 482 to 5,757 for each dataset. The superscript numbers in the header row
correspond to the reference numbers in the manuscript. wks: weeks.
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Figure 3. Shared transcriptional networks between murine and human datasets identified by TALE, a graph
matching software. Using a graphical matching software (TALE), each network generated using the murine datasets
were examined for overlap with the human gene network. The resulting networks are below with the number in
parenthesis representing the total genes within the network. Node size indicates amount of degree relative to the size of
the network.
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Table 5. The most commonly dysregulated differentially expressed genes among the shared transcriptional
networks. Shared network genes between each murine dataset and human dataset were identified. The fold change for
each dataset is represented by the value in each cell and the color displays the relative change within the table, with red
being an increased fold change and blue being a decreased fold change. Many of the represented DEGs are directionally
consistent across murine models but not necessarily between the human and murine comparison.
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Cytoscape was then used to visualize each shared TALE network. Each
individual shared network based on the TALE comparison between the human
dataset and each murine dataset is visualized in Figure 3. Networks were
merged using the merge network feature in Cytoscape in order to identify the
most connected DEGs (Figure 4). The top five most highly connected genes,
based on degrees within the merged network, were PIK3CA, MPAK8, CD44,
MAPK1, and CREB. These most connected genes are not biased by the amount
of dataset in which they appear, but instead depend on the connections that each
node has within the network. The majority of highly connected genes do appear
in four or more datasets and all genes are observed in our human data.
The genes in the shared transcriptional networks between human and
each murine model were analyzed for pathway enrichment using IPA. Over 380
pathways were found to be significantly enriched and the top pathways shared
across each network are shown in Table 6, which displays a fold change based
on the average fold change of the pathway genes identified by IPA. The
directionality is indicated by color (with red being an increase and blue being a
decrease) based on the percentage of genes involved that have increased or
decreased expression levels. These pathways were often directionally similar to
our human dataset, unlike the originally described DEGs. The T1DM STZ model
used in our study does display consistent up-regulation of the subset of enriched
pathways identified as shared across models in Table 6. The top pathways
shared across each network included LXR/RXR activation, agrin interactions at
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Figure 4. Highly connected DEGs across TALE networks. (A) TALE networks were combined using the merge
network feature in Cytoscape. Node size is based on the degree of connections and organized as a radial tree. (B) This
table shows the fold changes of the most highly connected genes in each dataset with red coloring being an increased
fold change and blue being a decreased fold change. A total of 688 genes were included in the network with the degree of
connections between genes ranging from 304 and 1. Each connection between genes were supported by a minimum of 3
citations as defined by SciMiner.
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Table 6. Disrupted Pathways Based on TALE DEGs. The most frequently perturbed pathways within each shared
network are represented in the table. The cell value indicates the average change in fold change for the genes involved in
this pathway while the color indicates the overall direction of the genes. Red indicates that more genes involved in the
pathway have increased expression while blue indicates the genes involved have decreased expression values. The most
common theme among these pathways are inflammation with multiple interleukin signaling pathway as well as some
autoimmune pathways commonly found in rheumatoid arthritis.
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neuromuscular junctions, hepatic fibrosis, and role of osteoblasts, osteoclasts,
and chondrocytes in rheumatoid arthritis. The common themes that underlie
these enriched pathways are lipid metabolism, extracellular matrix, and disrupted
inflammation.
Merged Transcriptional Network and Centrality Analysis
Seven human and murine shared networks were merged into a single network,
consisting of 688 genes that interacted with up to 304 other genes in the network
(Figure 4A). Using the sna package in R, this merged network was analyzed to
identify the most central and influential genes within the network. The four
measures of centrality used included closeness, betweenness, degree, and
eigenvector values. Table 7 lists the 14 most central genes that are ranked
among top 10 in each centrality measure. While these genes exhibit overlap with
Figure 4B, they also represent a more thorough and analytical measure of gene
influence within the network, while the previous figure assists in clarifying the
complex merged network. These genes include interleukin 1 beta (IL1B),
hepatocyte growth factor (HGF), c-c motif chemokine ligand 2 (CCL2), CD36,
FOS, and JUN. While transcription factors such as FOS and JUN are likely to be
central to a network as regulators of many genes, the inclusion of cytokine and
chemokines such as IL1B, HGF, and CCL2 further supports the involvement of
the immune system in DPN198,203–205.
The 14 most central genes were also used as input to IPA in order to
identify enriched pathways represented by these influential genes. The top 20
canonical pathways are shown in Table 8 with –log10(p-value) as a measure of
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significance; the ratio represents the proportion of the 14 central genes to all the
genes involved in the canonical pathway. Ratio values in this case are expected
to be low since our input gene list was only the 14 genes identified as most
central within the network. The most significant pathways include HMGB1
signaling and Glucocorticoid receptor signaling.
We further extended our pathway enrichment analysis to the 64 most
central genes, belonging to the top 50 in at least one centrality measure. Based
on gene overlap and shared directionality among pairs of these pathways, we
constructed a contextual similarity network in Figure 5, where edges from the top
25% similarity scores are included. InfoMap206, a network clustering algorithm,
was used to identify sub-networks or clusters that are highly interconnected.
These clusters shared common functional themes, and the largest cluster of
canonical pathways was associated with immune response and inflammation (in
green in Figure 5).
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Symbol

MAPK8

Description
phosphoinositide-3-kinase,
catalytic, alpha polypeptide
mitogen-activated protein kinase 8

372 (p=3.8E-07)

0.00078 (p=6.6E-01) 30937.8 (p=0.0E+00)

0.15 (p=6.3E-03)

CD44

CD44 molecule (Indian blood group) 349 (p=1.3E-08)

0.00075 (p=6.6E-01) 32129.4 (p=0.0E+00)

0.13 (p=7.3E-03)

MAPK1

280 (p=3.5E-03)

0.00074 (p=6.5E-01) 19719.2 (p=1.7E-03)

0.13 (p=3.9E-02)

283 (p=1.2E-08)

0.00073 (p=6.4E-01) 15524.7 (p=0.0E+00)

0.12 (p=3.0E-03)

LEP

mitogen-activated protein kinase 1
cAMP responsive element binding
protein 1
leptin

301 (p=8.7E-10)

0.00072 (p=6.6E-01) 22639.7 (p=0.0E+00)

0.12 (p=5.6E-03)

CCL2

chemokine (C-C motif) ligand 2

276 (p=3.3E-03)

0.00071 (p=6.9E-01) 13595.3 (p=4.5E-03)

0.12 (p=1.0E-01)

JUN

jun proto-oncogene

232 (p=5.9E-03)

0.00071 (p=6.7E-01) 11905.8 (p=1.2E-02)

0.12 (p=4.3E-02)

ESR1

estrogen receptor 1
FBJ murine osteosarcoma viral
oncogene homolog
CD36 molecule (thrombospondin
receptor)
interleukin 1, beta
hepatocyte growth factor
(hepapoietin A; scatter factor)

269 (p=4.7E-09)

0.00071 (p=6.6E-01) 17433.2 (p=0.0E+00)

0.11 (p=5.8E-03)

229 (p=3.1E-03)

0.00070 (p=6.4E-01) 21885.2 (p=2.5E-07)

0.10 (p=7.4E-02)

247 (p=5.0E-07)

0.00070 (p=6.5E-01) 11865.1 (p=6.5E-13)

0.11 (p=7.2E-03)

224 (p=6.5E-03)

0.00070 (p=6.6E-01) 12492.5 (p=3.4E-03)

0.09 (p=1.6E-02)

213 (p=9.4E-06)

0.00069 (p=6.6E-01) 8254.8 (p=2.6E-07)

0.12 (p=4.6E-03)

PIK3CA

CREB1

FOS
CD36
IL1B
HGF

Degree (p-value) Closeness (p-value) Betweenness (p-value) Eigenvector (p-value)
406 (p=1.8E-08)

0.00081 (p=6.4E-01) 43246.5 (p=0.0E+00)

0.16 (p=2.9E-03)

Table 7. Centrality Analysis Gene Results. Centrality analysis was conducted using the Cytoscape plug-in CentiScaPe
and four centrality metrics (degree, eigenvector, closeness, and betweenness) to identify the most important nodes (i.e.,
genes) in the merged transcriptional network. The top 10 ranked genes in each perspective centrality metric is included in
the table and indicate the most influential genes within the network. The centrality scores of each node were compared
against the background distribution of centrality scores that were obtained from randomly generated 1,000 random
merged networks. P-values were calculated using z-test to examine the significant difference between the real and
random networks.
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Ingenuity Canonical Pathways

-log10(p-value) Genes

Ratio

HMGB1 Signalling

14.2

FOS, PIK3CA, JUN, CCL2, MAPK1, MAPK8, IL1B, PLAT 0.06

Glucocorticoid Receptor Signalling

13.6

FOS, PIK3CA, JUN, CCL2, MAPK1, CREB1, MAPK8,
IL1B, ESR1

0.03

11.3

FOS, PIK3CA, JUN, MAPK1, CREB1, MAPK8

0.08

11.3

FOS, PIK3CA, JUN, MAPK1, CREB1, MAPK8

0.08

11.2

FOS, PIK3CA, JUN, MAPK1, CREB1, ESR1

0.08
0.07

GDNF Family Ligand-Receptor
Interactions
Neurotrophin/TRK Signalling
Estrogen-Dependent Breast Cancer
Signalling
LPS-stimulated MAPK Signalling

11

FOS, PIK3CA, JUN, MAPK1, CREB1, MAPK8

HGF Signalling

10.2

FOS, PIK3CA, JUN, MAPK1, HGF, MAPK8

0.05

Renin-Angiotensin Signalling

10.1

FOS, PIK3CA, JUN, CCL2, MAPK1, MAPK8

0.05

IL-6 Signalling

9.92

FOS, PIK3CA, JUN, MAPK1, MAPK8, IL1B

0.05

FOS, JUN, MAPK1, MAPK8, IL1B, ESR1

0.04

Aryl Hydrocarbon Receptor Signalling 9.66
Role of Macrophages, Fibroblasts and
Endothelial Cells in Rheumatoid
9.38
Arthritis
IL-2 Signalling
9.37

FOS, PIK3CA, JUN, CCL2, MAPK1, CREB1, IL1B

0.02

FOS, PIK3CA, JUN, MAPK1, MAPK8

0.08

UVB-Induced MAPK Signalling

9.3

FOS, PIK3CA, JUN, MAPK1, MAPK8

0.08

IL-10 Signalling

9.23

FOS, JUN, MAPK1, MAPK8, IL1B

0.07

EGF Signalling

9.23

FOS, PIK3CA, JUN, MAPK1, MAPK8

0.07

Acute Phase Response Signalling

9.17

FOS, PIK3CA, JUN, MAPK1, MAPK8, IL1B

0.04

Chemokine Signalling

9.14

FOS, JUN, CCL2, MAPK1, MAPK8

0.07

Toll-like Receptor Signalling

9.05

FOS, JUN, MAPK1, MAPK8, IL1B

0.07

CD40 Signalling

8.93

FOS, PIK3CA, JUN, MAPK1, MAPK8

0.06

Dendritic Cell Maturation

8.86

PIK3CA, LEP, MAPK1, CREB1, MAPK8, IL1B

0.03

Table 8. Top 20 IPA Canonical Pathways Based on the Most Central Genes.
The 14 genes identified by CentiScaPe to be the most central genes within the
merged network based on the four centrality measures were used as input for
IPA to analyze pathway enrichment. This table represents the enriched pathways
based on these genes with –log10(p-value) as a significance measure and the
ratio as the proportion of significant DEGs measured over the total genes within
the pathway. HMGB1 signaling, Glucocorticoid receptor signaling, as well as the
various interleukin pathways indicate disrupted inflammation as a central
influence within the cross-species shared network. The ratio represents the
proportion of the 14 central genes to all the genes involved in the canonical
pathway.
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Figure 5. IPA Enriched Pathway Clustering. The pathways found to be enriched by IPA based on the top 64
most central genes, belonging to the top 50 in at least one centrality measure, within the merged network. 272
canonical pathways determined significantly enriched by IPA were examined for their similarity in terms of gene
content and shared directionality among the pathways. Edges, connections between pathways, are only included if
their similarity scores were among the top 25%. InfoMap206, a network clustering package in R, was used to identify
clusters, which are represented in different colors. These clusters shared common functional themes, which are
noted in the figure. The largest cluster of canonical pathways were associated with immune response and
inflammation (in green). Colors of the node denote the clusters identified by InfoMap.
45

Discussion
In our first study, we compared transcriptomic changes in peripheral
nerves isolated from humans and mouse models of T1DM and T2DM at various
stages of DPN to identify potential molecular pathways contributing to disease.
We previously examined these changes during the development of DPN in both
mouse models and human patients177,178,180,181 and determined critical genes and
pathways that play an important role in DPN. However, no systematic
comparison of these transcriptomics datasets has been made. In the current
study, using our published datasets, transcriptomic changes were compared in
multiple mouse models of diabetes at different stages of the disease as well as in
human subjects with DPN. Changes in one human and seven murine microarray
datasets - at both the gene and pathway level – were examined using a single
unified analysis pipeline to identify common pathways involved in the
development of DPN. In total, we identified over 380 pathways that were
enriched across all data sets, providing new insights into DPN pathogenesis.
Many of the pathways that were dysregulated in our previous reports were
similarly dysregulated when compared across the seven murine models and
human samples, including pathways associated with immune system, cellular
development and cellular survival176,178,181,188,199. In addition, we show that key
pathways governing lipid metabolism (LXR/RXR, adipogenesis and PIK3CA) and
extracellular matrix homeostasis (chondrocytes, paxillin, and fibrosis), that have
been highlighted in our previous study, were also altered in the current setting178.
Consistent with previous reports, transcriptional changes associated with
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estrogen signaling were observed, as sex-specific risk levels for diabetic
complications have been well documented in human207 and mouse184,208 models.
In agreement with our previous studies176–178,182–184,199, we observed
transcriptomic and functional pathway changes in multiple immune-related
pathways in all of the data sets. In particular, our results indicate that key
pathways involved in the control of immune and inflammatory functions were
upregulated during DPN, including NF-κB and JAK/STAT pathways. In fact,
these pathways are activated in the DRGs of diabetic rats and have been
associated with nerve injury in diabetes188,209,210. Our findings support targeting
these pathways in murine models of diabetes to understand their
pathophysiological roles in DPN189,211. We found that both pro- and antiinflammatory cytokine pathways were dysregulated across data sets: IL-2, IL-6,
and IL-10 as well as chemokines were all altered in DPN. Studies have shown
that cytokines and chemokines not only promote existing inflammatory and
immune responses, but also induce oxidative and nitrosative stress, further
exacerbating cellular injury in experimental models of DPN212. In fact, during
inflammation, both pro- and anti-inflammatory pathways are often simultaneously
engaged as a disease process such as DPN transitions from active to chronic
inflammation. For instance, neuronal repair is initiated by neutrophils213 and
driven by macrophages214 under specific environmental conditions that are antiinflammatory; however, as the disease process progresses, the introduction of
pro-inflammatory signals overrides the anti-inflammatory response, resulting in
tissue destruction. This concept is established in neurodegenerative disorders
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such as amyotrophic lateral sclerosis215, and our data strongly suggest a similar
process is occurring in DPN.
The importance of the immune system is further highlighted by the fact
that many of the pathways we observed dysregulated across all murine models
and human samples, including those involved with transcription, cellular
development, and lipid metabolism are also involved in the immune response.
We show that HMGB1 signaling, which is centrally involved in the regulation of
gene transcription, is one of the most highly dysregulated canonical pathways.
However, HMGB1 is also secreted by macrophages and damaged cells and
mediates systemic inflammation216 by signaling through receptors such as the
Receptor for Advanced Glycation End-products (RAGE) and Toll-Like receptors
(TLRs), both of which have been implicated in obesity-driven inflammation and
DPN217–220. This signaling cascade may drive NF-κB pathway that further
exacerbates the inflammatory response and increases tissue damage.
Moreover, disrupted lipid metabolism is associated with inflammation.
PPAR-γ, a major regulator of lipid and glucose metabolism, is altered in murine
models as well as in human and has been previously implicated as a common
factor in both DPN and diabetic nephropathy176,180. Yet, PPAR-γ can also control
inflammation in macrophages and dendritic cells221,222. Besides its established
role in inflammation, the LXR/RXR system has emerged as a key regulator of
cholesterol, fatty acid and glucose homeostasis, and neuroprotection223–225.
Additionally, LXR/RXR has been increasingly shown to play an important role in
diabetic complications225–228. Interestingly, LXR/RXR is observed as a shared
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pathway across murine models222,229. To a further extent, our results show an
initial downregulation of the LXR/RXR pathway in the db/db mouse model after 8
weeks of diabetes and an upregulation at late stages of the disease. In contrast,
LXR/RXR expression was upregulated in the ob/ob mouse model throughout the
duration of diabetes and after 34 weeks of diabetes in STZ-induced T1DM mice,
while no data were reported at earlier time points for T1DM mice. Collectively,
our findings point toward a potential involvement of the LXR/RXR pathway in
DPN. Taken together, our data further support a pivotal role of the immune
system in DPN, though it is unclear from the current data to what extent this
involvement is a cause or consequence of neuronal damage. We are currently
addressing this question in both experimental198 and clinical settings
(https://clinicaltrials.gov/show/NCT02936843).
On a different note, while numerous pathways were dysregulated across
data sets, the direction of transcriptional change was rarely universal. For many
pathways, we found that mouse models of DPN and human tissue transcription
were differentially expressed in opposite directions; whereas pathways in mice
were upregulated, they were frequently downregulated in human patients. Similar
cross-species discrepancy in gene expression direction was also observed in
diabetic nephropathy between human and murine models189. There are several
potential explanations for these discrepancies. The first is that the kinetics of
murine and human DPN progression are different; we observed transcriptomic
changes in mouse models of DPN up to 24 weeks (T2DM) and 34 weeks
(T1DM), but it is unlikely these mice completely represent the advanced stages
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of DPN encountered in human after decades of disease. Tissue sources may
also account for these differences, as human data sets were obtained from sural
nerves while mouse data were collected from sciatic nerves. We are currently
exploring discordant transcriptomic dysregulation in the sciatic and sural nerves
of mouse models, as a similar effect may be occurring here.
Alternatively, the nature of the controls in each species may have
influenced the results. Whereas changes observed in the murine models are a
result of a diabetic versus non-diabetic comparison, human transcriptomic data
are a result of comparisons between progressive and non-progressive DPN. We
recently conducted a transcriptional network analysis of DPN progression using
the same db/db microarray data at 8, 16, and 24 weeks183 used in the current
study. This study identified various DPN progression-associated genes and
pathways, which were overlapping with those identified in the present study, such
as TLR signaling, dendritic cell maturation, LXR/RXR activation, and various
cytokine pathways. Furthermore, O’Brien et al.’s original publication on the ob/ob
mouse model data at 5 and 13 weeks177 included a similar comparative analysis
result. In this study, inflammatory mechanisms were found to have a critical role
in early development and progression of DPN, and genes related to
inflammation, immune response, and chemotaxis were highly enriched at 5
weeks rather than 13 weeks. Both studies identified MMP12 as the most
significantly up-regulated gene across different time points, which was also found
to be shared between human and murine DPN in the current study, suggesting
its potentially critical role in the progression of DPN in both the experimental and
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clinical settings. Finally, in order to compare changes between species, an
orthologue conversion was also used to convert murine gene identifiers to their
human equivalent genes; as such it is possible that some murine genes were not
captured in the current analyses.
We also found that many pathways that were downregulated or a mix of
up/down regulation in T2DM-driven DPN were strongly upregulated in the data
set from the T1DM STZ mouse model. To validate these data, we re-examined
the outlier parameters in the data set as well as the background levels of each
microarray; in both cases the exclusion criteria remained unmet (data not
shown). The STZ dataset was held to the same criteria as all other murine
models which allows for a unified comparison across models and species, yet we
still found that most of the detected pathways were highly upregulated in T1DM.
These data suggest that while similar molecular pathways are involved in DPN
progression, the utilization of these pathways may be very different in T1DM and
T2DM. This is supported by our previous study examining transcriptional
changes in diabetic peripheral neuropathy and nephropathy in both T1DM and
T2DM mouse models; we found that while there was a high transcriptional
concordance in diabetic nephropathy, DPN-associated pathways were often
highly discordant188. Together these data suggest that key molecular pathways
are commonly involved in DPN but that they may be differentially regulated in
T1DM and T2DM. This concept is further supported by our reports in man, where
a systemic review of clinical trials strongly suggest different pathogenic
mechanisms underlying DPN in T1DM versus T2DM230.
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In summary, our transcriptional network-based approach, integrating
multiple bioinformatics analyses, identified DPN-associated pathways that are
highly conserved across multiple murine models and human. Many of the
pathways identified highlight the importance of the immune system through
cytokine and chemokine signaling as well as the observed dysregulated
pathways associated with transcription, cellular development, and lipid
metabolism are all involved in the immune response. The observed conserved
pathways are likely the key responses in DPN and provide new therapeutic
targets for the potential treatment of DPN, a disorder that remains without a drug
intervention to date.
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CHAPTER III
CONSERVED GENE EXPRESSION CHANGES AND DYSREGULATED
PATHWAYS IN COMPLICATION-PRONE TISSUES OF STREPTOZOTOCININDUCED DIABETIC MICE
Abstract
Diabetic peripheral neuropathy (DPN) and diabetic nephropathy (DN) are
two common complications of diabetes that are associated with a high degree of
morbidity. Currently, treatments only manage the symptoms of these
complications rather than targeting cause of the disease. There is therefore a
critical need to identify treatment strategies that impact the underlying disease
pathogenesis. In this study, diabetes was induced in Male C57BLKS db/+ mice
with a single high-dose 150 mg/kg (i.p.) streptozotocin (STZ) injection at 6 weeks
of age. STZ-treated mice developed type 1 diabetes mellitus (T1DM)
phenotypes: significantly lowered body-weight and insulin level, and highly
elevated levels of fasting glucose, triglyceride and cholesterol. Sciatic nerves,
dorsal root ganglia, kidney renal cortex, and glomeruli tissues were harvested at
16 weeks of age and examined for differential expression between control and
STZ-diabetic mice using an RNA-Sequencing (RNA-seq) approach. We identified
differentially expressed genes (DEGs) ranging from 76 to 4130 in four tissues.
242 DEGs were common in three or more tissues, with three quarters of genes
displaying concordance in the directions of expression change across tissues.
We also identified 309 significantly enriched pathways, 38 of which were shared
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across at least three tissues. Network analysis revealed clusters of pathways
involving oxidative stress, cell cycle regulation, and inflammation as being
important enriched pathways from the list of concordant genes. These findings
provide transcriptomic profiles of complication-prone tissue in the STZ model of
T1DM and describe factors influencing both DPN and DN.
Introduction
T1DM accounts for approximately 5% of the diabetic population and
typically describes the autoimmune destruction of pancreatic β cells leading to
insulinopenia and systemic hyperglycemia231. This condition is managed through
rigorous insulin therapy but even under strict glycemic control patients can
experience the microvascular complications associated with T1DM. DPN and DN
are two of the most common complications associated with diabetes occurring in
20% of patients with T1DM232–234.
DPN is characterized by the chronic, symmetrical, and distal degeneration
of peripheral nerves in a progressive manner leading to symptoms including pain,
hypersensitivity, and burning or tingling sensations235. Progression of this
condition can lead to the loss of sensory input and is often associated with the
diabetic foot condition which is the leading cause of non-traumatic lower limb
amputations236. DN involves the loss of kidney function and is the leading cause
of end stage renal disease (ESRD) accounting for around 50% of cases237. DN is
often identified by proteinuria due to glomeruli damage, such as basement
membrane thickening, which can lead to low serum albumin levels. DN is usually
a slowly progressive condition but due to current treatments limitations, ultimately
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many patients reach ESRD. These complications are in dire need of mechanismbased therapies and to better examine these diseases many animal models have
proven invaluable to the support of basic and translational studies aiming to
uncover novel therapeutic strategies192,238.
The most common model used to study T1DM is the STZ-induced model.
STZ is a glucosamine-nitrosourea compound isolated from Streptomyces
achromgenes as a broad spectrum antibiotic and antineoplastic agent239. Single
high dose (SHD) or consecutive multiple low dose (MLD) of STZ can induce a
T1DM like condition in murine models by ablating pancreatic β cells through the
glucose transporter 2240,241. These dosing paradigms have been shown to have
critical differences with SHD having a robust and early complication phenotype
as well as high mortality while the MLD regiment exhibits a low to moderate
complication phenotype242–244.
This study utilized the SHD paradigm to examine the transcriptomic
changes occurring in DPN (sciatic nerve and dorsal root ganglia) and DN
(glomeruli and renal cortex) prone tissues. Many transcriptomic studies have
been conducted using microarray data in an attempt to investigate underlying
causes of diabetic complications which have indicated mechanisms involving
inflammation, oxidative stress, as well as various metabolic processes176,180,245.
Comparisons between DPN and DN have been previously conducted in an effort
to identify a possible unified approach to treating these microvascular
complications associated with T1DM and type 2 diabetes mellitus (T2DM)246,247.
However, the significance of this study is that it examines and compares the
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transcriptomic profiles in the STZ-model of T1DM in an effort to identify possible
shared mechanisms.
Methods
Sample Collection and Processing
Male C57BLKS (BKS) db/+ were fed a standard diet (AIN76A; 11.5% kcal
fat; Research Diets, New Brunswick, NJ, USA) and cared for in a pathogen-free
environment by the University of Michigan Unit for Laboratory Animal Medicine.
Diabetes was induced in BKS db/+ mice with a single high-dose 150 mg/kg (i.p.)
STZ injection at 6 weeks of age. STZ-treated mice developed T1DM phenotypes
according to Diabetic Complications Consortium guidelines248,249 including
significantly lowered body-weight and insulin level, and highly elevated levels of
fasting glucose, triglyceride and cholesterol (Figures 6,7,8).
Total RNA was isolated from sciatic nerves (SCN, n=6), dorsal root
ganglia (DRG, n=6), kidney renal cortex (Cortex, n=6), and glomeruli (Glom, n=6)
tissues harvested at 16 weeks of age from both untreated and STZ-treated BKS
db/+ mice. RNA quality was evaluated using TapeStation (Agilent, Santa Clara,
CA) with an RNA integrity number of ≥8 as the cutoff for further sample
processing with the Illumina TruSeq mRNA Sample Prep v2 kit (Catalog #s
RS122-2001, RS-122-2002; Illumina, San Diego, CA, USA). Resulting cDNA was
sequenced with a paired-end read length of 100 bases using an Illumina HiSeq
2000 (Illumina, Inc., San Diego, CA, USA) by the University of Michigan DNA
Sequencing Core (http://seqcore.brcf.med.umich.edu/).
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Metabolic phenotyping
Figure 6. Metabolic Phenotype db/+ mice testing following STZ treatments.
Metabolic phenotyping including body weight (A), fasting blood glucose (B),
fasting plasma insulin (C), and glycated hemoglobin (D).
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Neuropathy phenotyping
Figure 7. Neuropathy Phenotype db/+ mice testing following STZ
treatments. Neuropathy phenotyping included sural nerve conduction velocity
(NCV) (A), sciatic NCV (B), and hindpaw withdrawal latency (C).
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Nephropathy phenotyping
Figure 8. Nephropathy Phenotype db/+ mice testing following STZ
treatments. (C) Nephropathy phenotyping included glomerular periodic-acid
schiff (PAS)-positive area (A), Mesangial Index (B), glomerular area (C), and
albumin/creatinine ratio (D). All measurements were taken at 16 weeks of age in
all mice. *, p<0.05, **, p<0.01, ***, p<0.001, NS, not significant.
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Raw sequencing reads were cleaned using Trimmomatic to remove reads with
adapter or Poly-N sequences as well as reads with a quality score <30250. Quality
control assessment of RNA-Seq data was completed using the FastQC version
0.10.1251. Cleaned reads were mapped to the mouse reference genome m38.p6
Refseq using HISAT2252. FeatureCounts253 was used to count uniquely mapped
reads while genes with zero expression across samples were omitted from
differential expression analysis. Fragments per kilobase of exon per million
mapped reads (FPKM) as a measurement of transcript expression were
calculated using an in-house script.
Differential Expression and Pathway Enrichment
Differentially expressed genes (DEGs) were identified using the DESeq2
R package254. All genes with a Benjamini-Hochberg adjusted p-value less than
0.05 were determined to be differentially expressed between untreated and STZtreated groups for each tissue type. These DEG lists were used as input for
Ingenuity Pathway Analysis (IPA, QIAGEN Inc.,
https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis) to
determine significantly enriched canonical pathways based on a negative log pvalue greater than 1.3255. All four tissue types were analyzed for unique and
overlapping DEGs and pathways.
Network Clustering
DEGs with shared directional changes across tissues were used as input
gene sets for canonical pathway enrichment analysis through IPA. Pathways
were determined to be significantly enriched based on a negative log p-value
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greater than 1.3 and were then examined for their similarity of gene content.
Gene overlap within each pathway were used to determine network edges, while
pathways are represented as nodes. The R package InfoMap was used to
identify clusters of highly interconnected pathways256.
Results
Changes in Gene Expression
Global gene expressions were profiled in Cortex, Glom, DRG, and SCN
isolated from the STZ-induced murine model of T1DM. DEGs were determined
based on a comparison between STZ-treated animals and untreated control
animals with a sample size of 6 for each group although one SCN sample from
the STZ-treated group failed our quality control assessment. Each tissue had a
varying number of DEGs identified with cortex having the most (4,130 DEGs) and
DRG holding the least (76 DEGs) while the remaining tissues were much closer
in terms of total DEGs with Glom (2,719 DEGs) and SCN (2,621 DEGs).
Figure 9A illustrates the overlap among the four DEG sets identified from
each tissue. Of the DEGs only 242 were shared across three or more tissues.
While there is a low amount of conserved expression changes across tissues,
the overlapping DEGs show a high degree of similarity in regard to direction with
188 concordant and 54 discordant genes across tissue types (Figure 9B). Five
genes were differentially expressed across all 4 tissues and down-regulated in all
cases except for Galnt16 in the renal cortex (Table 9). Approximately, half of the
DEGs, were found to be unique to the specific tissue except for DRG. The DRG
samples had a low number of unique genes with only 32% (24 genes) most likely
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due to the low total DEGs identified. The other tissue samples had 52% (SCN,
1368), 55% (Glom, 1496), and 63% (Cortex, 2597) unique gene expression.
Enriched Canonical Pathways
Complete DEG lists were analyzed using IPA to determine enriched
canonical pathways. Pathways were determined to be significantly enriched with
a –log p-value greater than 1.3. Cortex had the most enriched pathways
represented by the DEG list with 182 while DRG had the least with 36. The other
tissues, SCN and Glom, had 104 and 162 pathways, respectively. The pathways
identified totaled 309 with 6 enriched in all four tissue types and another 32 in at
least three tissues (Figure 10). Pathway directionality was not always able to be
determined based on Z-score. However, among the top six enriched pathways,
acute phase response signaling and colorectal cancer metastasis signaling
appear to be up-regulated in nephropathy and down-regulated in neuropathy
(Table 10). Within the top six enriched pathways, PI3K/AKT signaling according
to the Z-score was down-regulated in all tissues besides DRG. The discrepancy
with DRG in this case is likely due to the low gene input being inadequate to
calculate the Z-score. Within the larger list of pathways shared across at least
three tissue types for which a Z-score was calculated, there are some interesting
patterns. Signaling pathways such as p53, protein kinase A, and ILK all showed
similar directional changes across tissues.
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B

Figure 9. Gene Overlap Common between Complication-Prone Tissue. (A)
The bar graph represent the overlapping differentially expressed (DEG) genes
common among tissue types. (B) The venn diagram shows the proportion of
DEGs common across at least three tissue types with either concordant or
discordant expression changes.
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Gene
Symbol
Gm10639
Galnt16
Txnip
Mt2
Mt1
Slc25a16
Exoc5
Mgea5
Agfg2
Brap
Agt
Shank3
Tc2n
Prss23
Pnpla2

Description

Cortex DRG Glom SCN

predicted gene 10639
Polypeptide NAcetylgalactosaminyltransferase 16
thioredoxin interacting protein
metallothionein 2
metallothionein 1
solute carrier family 25 (mitochondrial
carrier, Graves disease autoantigen),
member 16
exocyst complex component 5
meningioma expressed antigen 5
(hyaluronidase)
ArfGAP with FG repeats 2
BRCA1 associated protein
angiotensinogen (serpin peptidase
inhibitor, clade A, member 8)
SH3/ankyrin domain gene 3
tandem C2 domains, nuclear
protease, serine, 23
patatin-like phospholipase domain
containing 2

-6.42

-1.95

-2.41

-1.90

1.20

-0.96

-0.82

-1.05

-1.40
-2.48
-2.06

-1.56
-1.97
-1.42

-0.87
-4.13
-2.81

-0.80
-2.26
-1.74

-0.34

-0.45

-0.47

-0.39

-0.40

-0.37

-0.37

-0.54

-0.39

-0.77
-0.34

-1.04
-0.31

-0.81
-0.38

-2.19

-1.62

-1.51

0.53
1.30
-0.74

-0.76
-1.44
-0.80

-0.66
-1.61
-0.84

-1.43

-0.78

-1.13

Table 9. Gene Overlap Common between Complication-Prone Tissue. Each
tissue was analyzed for differential expression using the DESeq2 package in R
with an adjusted P value<0.05 as the significance cutoff. The color gradient and
values within the table are log2 fold change for each gene within the tissue
columns.
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Figure 10. Enriched Pathways Common Between Complication-Prone
Tissue. The bar graph represents the overlapping canonical pathways identified
by IPA common among tissue types.
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Ingenuity Pathway Analysis
Cortex DRG Glom SCN
Enrichment
Acute Phase Response Signaling
Adipogenesis pathway
Colorectal Cancer Metastasis Signaling
Role of Macrophages, Fibroblasts and
Endothelial Cells in Rheumatoid Arthritis
PI3K/AKT Signaling
PTEN Signaling
Molecular Mechanisms of Cancer
Axonal Guidance Signaling
p53 Signaling
Hepatic Fibrosis / Hepatic Stellate Cell
Activation
Aryl Hydrocarbon Receptor Signaling
Glioblastoma Multiforme Signaling
Aldosterone Signaling in Epithelial Cells
Germ Cell-Sertoli Cell Junction Signaling

4.51
2.34
2.81

2.10
1.38
1.66

1.76
3.47
1.95

1.50
2.22
2.28

2.56

1.41

2.58

2.02

1.78
1.77
6.99
2.77
6.41

1.44
1.47

2.19
2.40
4.97
6.26
4.00

1.77
1.43
4.87
6.29
3.41

3.00

2.95

7.65

3.93
2.67
2.70
2.73

2.87
3.93
1.82
3.54

5.30
3.86
4.05
2.02

Table 10. Enriched Pathways Common Between Complication-Prone
Tissue. Each DEG set was analyzed for pathway enrichment using IPA then
compared to identify common canonical pathways across tissues. The numbers
within the table are -log (p values) representing significant enrichment while
colors represent Z-scores indicating pathway directionality. Colorless boxes
represent no directional change or a Z-score which could not be calculated.
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Conversely, glioblastoma multiforme signaling, glioma invasiveness signaling,
and integrin signaling was up-regulation in DN and down-regulated in DPN,
suggesting different roles between complications. Insulin receptor signaling was
down-regulated in DN related tissues while no Z-score was able to be calculated
for DPN associated tissues.
Network Analysis of Concordant Gene Pathways
To further investigate possible shared characteristics influencing multiple
complications, we isolated the 188 concordant genes out of the 242 genes
shared across at least three tissues and used this list as input for IPA. The
resulting list of enriched pathways was subjected to network analysis by
evaluating for gene overlap to form the edges while pathways served as nodes
(Figure 11). InfoMap was then used for community structure analysis which
identified five different clusters within the network. This network level analysis
explores the interconnections shared across our tissue datasets based on genegene associations in order to find related/associated pathways.
The main green cluster involving 17 out of 29 total pathways is a dense
group involving pathways related to DNA damage stress responses, oxidative
stress, immune response, and cell cycle. The blue cluster of five pathways is
related to reactions in response to oxidative stress and maintaining a reducing
environment257,258. The red cluster of four pathways includes metabolic pathways
involved in both salvage and biosynthesis. The smallest clusters of one and two
nodes also involve immune response with antigen presentation and histamine
biosynthesis.
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Figure 11. Clustering of Enriched Concordant Pathways. IPA identified 29
significantly enriched canonical pathways based on the list of 188 concordant
genes shared across at least three tissue types. Pathways were then examined
for their similarity of gene content to determine edges. InfoMap256, a network
clustering package in R, was used to determine clusters as represented by the
differently colored nodes.
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This small cluster has roles in multiple systems but its immune response is most
evident in the context of the other network elements259,260. These network-level
data of concordant shared genes indicate that both DPN and DN complications
involve immune system response, oxidative stress, and cell cycle regulation in
T1DM.
As expected, some pathways involved in our concordant DEG network
were also enriched across 3 or more including glucocorticoid receptor signaling,
aldosterone signaling in epithelial cells, p53 signaling, d-myo-inositol (1,4,5)triphosphate biosynthesis, and PI3K/AKT signaling. Most other pathways
involved in our network were also enriched in one or two individual tissues such
as the NRF2-mediated oxidative stress response being upregulated in both DN
associated tissues (Table 11).
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Ingenuity Canonical Pathways

-log(pRatio z-score
value)

Molecules

NRF2-mediated Oxidative Stress Response

2.96

0.04

NaN

Glucocorticoid Receptor Signaling
IL-17A Signaling in Fibroblasts
Salvage Pathways of Pyrimidine
Ribonucleotides
Histamine Biosynthesis
Unfolded protein response
GADD45 Signaling
Antioxidant Action of Vitamin C
Aldosterone Signaling in Epithelial Cells
p53 Signaling
Pyridoxal 5'-phosphate Salvage Pathway
Proline Degradation
PPARÎ±/RXRÎ± Activation
Lipid Antigen Presentation by CD1
PI3K/AKT Signaling
D-myo-inositol (1,4,5)-Trisphosphate
Biosynthesis
Biotin-carboxyl Carrier Protein Assembly
VDR/RXR Activation
Glutathione-mediated Detoxification
ATM Signaling
Hereditary Breast Cancer Signaling
Arsenate Detoxification I (Glutaredoxin)
Ascorbate Recycling (Cytosolic)
Glutathione Redox Reactions II
PEDF Signaling
Antigen Presentation Pathway
PPAR Signaling

2.58
2.54

0.03
0.09

NaN
NaN

GSTA5,JUNB,DNAJB2,FKBP5,MAFF,ENC1,GST
O1
BCL2L1,NFKBIA,HSP90AB1,SGK1,FKBP4,CEB
PB,FKBP5,AGT
NFKBIA,LCN2,CEBPB

2.11
2.09
1.98
1.98
1.92
1.90
1.88
1.79
1.79
1.78
1.72
1.71

0.04
1.00
0.05
0.11
0.04
0.03
0.04
0.05
0.50
0.03
0.08
0.03

NaN
NaN
NaN
NaN
NaN
NaN
NaN
NaN
NaN
0
NaN
0

NME3,PIM1,SGK1,HIPK1
HDC
CALR,PDIA6,CEBPB
GADD45B,GADD45G
PLCB4,NFKBIA,PDIA3,GSTO1
PLCB4,HSP90AB1,PDIA3,SGK1,DNAJB2
HDAC9,BCL2L1,GADD45B,GADD45G
PIM1,SGK1,HIPK1
LOC102724788/PRODH
PLCB4,NFKBIA,HSP90AB1,PDIA3,INSR
CALR,PDIA3
BCL2L1,NFKBIA,HSP90AB1,INPP5K

1.69
1.61
1.58
1.58
1.55
1.51
1.49
1.49
1.49
1.46
1.41
1.36

0.07
0.33
0.04
0.06
0.04
0.03
0.25
0.25
0.25
0.03
0.05
0.03

NaN
NaN
NaN
NaN
NaN
NaN
NaN
NaN
NaN
NaN
NaN
NaN

PLCB4,PI4K2A
ACACB
CXCL10,CEBPB,KLF4
GSTA5,GSTO1
NFKBIA,GADD45B,GADD45G
HDAC9,GADD45B,GADD45G,WEE1
GSTO1
GSTO1
PDIA3
BCL2L1,NFKBIA,PNPLA2
CALR,PDIA3
NFKBIA,HSP90AB1,INSR

Table 11. Concordant Gene IPA results from Complication-Prone Tissues.
IPA enriched pathway results from our list of concordant DEGs are listed above.
Ratio indicates the number of genes included in our submitted list to their total
annotation list for that canonical pathway. Z-scores are used to determine
directionality. NaN indicates when a Z-score cannot be calculated and 0 indicates
no directionality based on the submitted genes and their fold change.
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Discussion
Bioinformatics analysis in previous studies examined the shared factors
between DPN and DN. However, no study has specifically examined the STZmodel of T1DM with a RNA-seq transcriptomic approach. While both T1 and
T2DM have related phenotypes in terms of their complications, these diseases
have quite different incidences of complications. For example, T1DM
complications such as DPN and DN have an incidence rate of approximately
20%, while 42-45% of T2DM patients will also experience these
complications261,262. Differences between T1 and T2DM complications extend
beyond the rate of incidence. For instance, development of changes and
neurotrophic support also leading to separate outcomes despite similar
hyperglycemic conditions263–266. Findings such as these indicate a direct need for
examination of T1DM complications as unique in order to develop future
approaches for treating and preventing these complications.
The DRG dataset clearly showed a lower amount of expression change
due to STZ treatment with only 76 DEGs compared to the other tissues which
identified from 2,621 to 4,130 DEGs. The separation seen within the PCA plot
suggests that this tissue was not heavily affected by the 10 weeks of
hyperglycemia following STZ treatment (Figure 12). However, despite the minor
gene expression changes induced in DRG tissue, mice involved in this study still
demonstrated clear changes in neuropathic phenotyping (Figure 7). Due to the
individual treatment of each tissue, the low amount of DEGs influence our
conserved analysis by weighting the study more heavily toward tissues affected
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Figure 12. Principal Component Analysis of Four Tissues in STZ Treated
Mice and Wild Type Controls. Principal component analysis (PCA) uses an
orthogonal transformation to convert correlated variables into linear uncorrelated
variables so that variance between samples can be visualized in the dot plot
above. Each tissue groups into separate clusters although samples from both
STZ treated and wild type mice intermix within those clusters.
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by DN complication rather than DPN. While the conserved genes were most
often represented in cortex, glomerulus, and sciatic nerve we had very little
contribution to the total genes from the DRG tissue. However, despite this
caveat, this study has identified potentially critical genes, pathways, and
functions that may influence both DPN and DN in T1DM.
The initial examination of genes in the kidney and nerve of the SHD-STZ
model after 10 weeks of hyperglycemia in this study revealed that although a low
number of genes were disrupted in both DPN and DN, the genes affected in both
conditions often showed a similar change when compared to healthy tissue. Over
three quarters of shared genes showed a concordant directional change across
tissues indicating that these shared genes are most often being influenced in a
similar way for both conditions. DRG was the only tissue which did not
demonstrate discordant expression directionality within the genes shared across
three or more tissues. The other three tissues all had discordant genes with
Cortex having the most (22) followed by Glom (16) and then SCN (15). The
genes with discordant or opposite directionality between complication tissues
need to be carefully considered whenever proposing treatments as these targets
may exacerbate one condition while assisting in another. Roughly half of the
genes identified as differentially expressed when comparing complication-prone
tissue in our STZ-model to the healthy control were unique to the tissue used
with the exception of DRG being 32% unique likely due to the low total DEGs.
These unique DEGs should also be considered for similar reasons as discordant
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genes but are most likely unique due to the different gene expression profiles of
separate tissues.
In an effort to further elucidate the cellular systems influencing DPN and
DN of the STZ T1DM model, pathway analysis of DEGs through IPA was also
performed on each tissue as well as on the list of DEGs shared across three or
more tissues. Unlike the DEGs shared across tissues which shared a high
amount of concordance, the pathways shared across tissues between DPN and
DN tissues. Out of 38 shared pathways, 21 were unable to support the Z-score
calculation in any tissue (Table 11). However, it is of note that based on the low
DEG count of DRGs, no Z-score was able to be calculated for the enriched
pathways from DRG tissue. Within the group of pathways enriched in three or
more tissues, acute phase response signaling, colorectal cancer metastasis
signaling, glioblastoma multiforme signaling, glioma invasiveness signaling, and
integrin signaling were all up-regulated in DN and down-regulated in SCN.
Shared concordant pathways included ILK signaling and protein kinase A
signaling which were up-regulated while PI3K/AKT signaling and p53 signaling
were down-regulated. Many of the above pathways revolve around cell
proliferation, cell cycle progression, and cell motility in a way that these cellular
processes are increased in DN and decreased in DPN. This indicates that
progression in both diseases is being observed through proliferation within the
kidney tissue and degeneration in the sciatic nerve tissue267–269.
Pathway analysis was also performed on the list of 188 concordant genes
across tissues. To investigate connections and synergies between complications
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the pathway results from concordant genes were also subjected to network
analysis with overlapping genes as edges while pathways served as nodes.
When compared with the list of shared DEGs, the concordant pathway network
also showed shared edges (genes) between five pathways enriched within the
full DEG data for each tissue as well. These pathways include D-myo-inositol
(1,4,5)-trisphosphate biosynthesis, p53 signaling, aldosterone signaling in
epithelial cells, glucocorticoid receptor signaling, and PI3k/AKT signaling which
share BCL2L1, HSP90AB1, NFKBIA, and PLCB4. These genes were
differentially expressed in all tissues, besides DRG, with HSP90AB1 and PLCB4
being upregulated while NFKBIA and BCL2L1 are downregulated. These genes
are involved in the cell survival components of these pathways and may be an
important influence in the progression of complications via their involvement in
multiple pathways affecting three of our complication-prone tissues.
Network analysis also identified clusters of pathways associated with
inflammation and oxidative stress as important components involved in the
concordant expression profile across tissues (Figure 11). Oxidative stress and
the glutathione pathways involved in our network structure specifically, have
been shown to be directly linked to the risk of kidney complications in T1DM258.
Inflammation has also been heavily linked to the progression of diabetic
complications132,270–274. The pathways involved in our network influencing
inflammatory response include glucocorticoid receptor signaling, IL-15
production, histamine biosynthesis, and the antigen presentation pathways.
These pathways have been previously linked to diabetic complications with
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elevated histamine levels observed in diabetic patients and linked to peripheral
vascular diseases275. Glucocorticoids have been shown to induce a similar
neurochemical pattern to a diabetic state in DPN276. PPAR signaling is also
involved in our network structure and has been a therapeutic target of T2DM.
Pioglitazone, a PPAR agonist, has been shown to have a therapeutic benefit in
DN and for reducing neuropathic pain and nervous system inflammation in
DPN247,277–280. Based on links within the literature, these pathways are also likely
involved in the progression of diabetic complications in peripheral nerve and
kidney tissues as observed in this study.
In a previous manuscript from our lab examining both DN and DPN in
T1DM and T2DM using microarray data we observed both similar results188. The
previous study examined common dysregulation between T1DM and T2DM.
Gene expression in DPN tissue differed between T1DM and T2DM and DN
tissue had similar expression patterns between T1DM and T2DM. The data
presented here investigated multiple tissues for DN (Glom and Cortex) and DPN
(SCN and DRG) while the previous study only examined Glom and SCN. Our
previous study saw 62% concordance between DN and DPN in STZ-treated mice
while we saw slightly higher with 77.7% of shared genes also sharing a
directional change. Similar pathway enrichment reflecting oxidative stress and
inflammation were also identified by both studies.
In summary, our comparison of the transcriptomic profiles of nephropathy
and neuropathy prone tissues using the STZ-model of T1DM indicate that
oxidative stress, cell cycle regulation, and immune response are important
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factors conserved between conditions. These findings support previously
identified factors influencing microvascular complications in T1DM and provide
transcriptomic profiles of multiple tissues within the SHD STZ-model of the
disease.
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CHAPTER IV
ΑLPHA-SYNUCLEIN-INDUCED METHYLATION AND GENE EXPRESSION
CHANGES IN MICROGLIA
Abstract
Parkinson’s disease (PD) is the second most common neurodegenerative
condition characterized by loss of dopaminergic neurons, α-synuclein
accumulation, and neuroinflammation. Alpha synuclein (α-syn) has been
implicated as a contributing factor in PD and can induce an innate immune
response in the brain281,282. This protein is tightly regulated by methylation,
however, the influence α-syn can have on methylation and expression patterns
has not been examined281–286. Here we used reduced representation bisulfite
sequencing (RRBS) to determine DNA methylation changes and RNAsequencing to examine gene expression changes induced in microglia, the
innate immune cell of the brain, by α-syn. The mThy1-Asyn mouse, which
overexpresses human α-syn as a model of PD, has been used to study the
influence α-syn has on microglia activation. Microglia DNA and RNA were
isolated at 3 and 13 months of age from these mice and used for RRBS and
RNA-sequencing to capture genomic methylation changes at CpGs and changes
in gene expression. These transgenic mice have been shown to present markers
of neuroinflammation as early as 1 month and begin to show motor and nonmotor symptoms at 3 months similar to a pre-parkinsonian phenotype.
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Reduction in dopamine levels and a more severe phenotype are observed at 14
months indicating an early stage Parkinson’s phenotype. At 3 months, 27,175
differentially methylated CpGs (DMCs) were identified between healthy and
transgenic mice representing 5,315 unique genes and 119 differentially
expressed genes (DEGs). Identified genes represented by our DMCs
(differentially methylated genes, DMGs) and DEGs from RNA-seq were subject
to enrichment analysis using Gene Ontology (GO), Kyoto Encyclopedia of Genes
and Genomes (KEGG), and Reactome pathways annotation databases.
Biological functions related to adhesion, cellular movement, synaptic
transmission, and immune functions were over-represented within our lists of
DMGs and DEGs at 3 months, suggesting a possible shift to an activated
microglia phenotype at an early stage of PD. The more phenotypically advanced
mice at 13 months had 15,226 DMCs representing 3,742 DMGs and 3,766
DEGs. Enriched biological functions and pathways related to migration,
adhesion, proliferation, and cellular metabolism/mitochondrial dysfunction were
identified from our DEG and DMG lists at 13 months. Network analysis was also
used on each dataset to further elucidate possible connections within the data.
Networks produced from 3-month DMGs and DEGs were heavily influenced by
immune and migration terms. While 13-month networks involved terms related to
metabolism and proliferation linked to neurodegenerative functions. Migration
and adhesion functions with an emphasis on cell surface interaction were also
prominent. Possible correlations between changes in methylation and gene
expression were investigated, but the only significant correlation was a negative
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correlation with increased methylation in intronic DMCs associated with a
decrease in gene expression. Overall, α-syn-induced changes in methylation and
gene expression observed in microglia were related to immune response,
synaptic transmission, and cellular movement in early stages. Then shifted to cell
cycle, immune response, and metabolism in later stages. These pathways are
associated with an active immune response from microglia, which influence
synaptic transmission as well as induce apoptosis and phagocytose dead
cells287–290.
Introduction
Parkinson’s disease (PD) is a common neurodegenerative condition
associated with the loss of dopaminergic neurons in the substantia nigra. The
loss of dopamine signaling accounts for motor symptoms of PD, including
tremors, rigidity, slowness of movement, and postural instability28. Patients often
experience nonmotor symptoms such as depression, anxiety, sleep disorders,
constipation, and cognitive impairment291. A hallmark of this disease is protein
aggregates called Lewy bodies, which are primarily composed of α synuclein292.
Alpha synuclein (α-syn) is a protein whose oligomerization and
aggregation have been implicated as a contributing factor to a variety of
neurodegenerative diseases such as dementia with Lewy bodies, multiple
system atrophy, and PD281. The function of α-syn is still a subject of debate, but it
has been shown to be involved in regulating synaptic transmission and
transcription293–297. α-syn is highly enriched at the synapse co-localizing with
reserve pools of synaptic vesicles and involved with synaptic vesicle cycling,
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vesicle pool size, mobilization, and endocytosis298,299. Both histone and direct
DNA interactions have been shown with α-syn in the nucleus through binding to
gene promoters and regulation of acetylation-deacetylation cycles of histones300–
303

. Due to the diverse function of α-syn, it is tightly regulated at multiple levels.

Transcriptional regulation involving epigenetics such as micro RNAs (miRNA)
and particularly DNA methylation have been shown to play a key role in gene
expression of α-syn283–286. Reduced DNA methylation has been reported to lead
to increased α-syn levels in the brain of PD and patients experiencing dementia
with Lewy bodies303,304. While α-syn has been shown to influence histone
acetylation, its influence on genomic methylation patterns has yet to be
investigated302. Methylation plays a critical role in the regulation of α-syn and the
ability to influence changes in methylation may create a positive feedback loop
contributing to disease progression283. However, the influence α-synuclein has on
DNA methylation and gene expression patterns have not been thoroughly
explored. Transcriptional and post-translational mechanisms regulating
expression levels may play a critical role in PD development305.
A common challenge to studying α-syn is the heterogeneity of structures it
can be found in281. Various in vitro studies suggest that α-syn is predominantly a
monomer in its native state, but conformational changes can be induced by a
wide variety of processes306–313. In disease conditions, α-syn oligomers are found
in axons and presynaptic terminals where they may damage axons and
presynaptic terminals314–319. To overcome the challenge of structural diversity, in
vivo models have been designed, which overexpress the SNCA gene313,320,321.
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While some models overexpress mutant forms of SNCA, such models only
represent the familial form of the disease, which accounts for around 27% of
cases322. Models expressing unmutated forms of α-syn may better recapitulate
the progression of PD in idiopathic cases323–325.
. The murine model used in this study drives overexpression of full-length
human wild-type α-syn under the murine Thy-1 promoter (mThy1-Asyn). This
model demonstrates progressive motor and nonmotor symptoms, loss of striatal
dopamine, α-syn associated pathology, and similar neuroinflammatory markers
typically found in PD patients96. These mice present with 1.5-3.4-fold higher αsyn expression than littermate controls. These levels are close to that observed
in patients with a familial form of PD with a gene triplication of α-syn96. The
symptoms these mice experience are progressive; however, no loss in the
amount of dopaminergic neurons have been recorded96,97. As such, they are
often considered as an early-stage progressive model of PD. As early as one
month of age, an active immune response was observed through elevated
mRNA of cytokines and activated microglia103,326. Motor and non-motor
symptoms become evident at 3 month, which has been observed using various
motor and behavioral tests98,99. Dopamine levels rapidly decrease at 14 months
along with increase mortality96. The time points selected for our study revolve
around these observed phenotypic changes. The three-month time point is after
initiation of inflammation and once a phenotype begins to develop, representing a
pre-parkinsonian time point. The 13-month time point demonstrates an early
stage of PD directly before the decline in dopamine levels that occurs at 14
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months. These critical time points of initiation of neuroinflammation and
progression of PD symptoms provide the opportunity to identify potential
biomarkers and therapeutic targets associated with α-synuclein-induced
inflammation.
The increase inflammation and activated microglia in this model are
consistent with the neuroinflammation measured in patients99–101. Microglia are a
particular cell of interest in the initiation and progression of PD based on their
involvement in the immune response which can be engaged via aggregated αsyn282. The M1 activated status is associated with a proinflammatory phenotype
and expression of various cytokines and neurotoxic compounds327–331.
Alternatively, an M2 state related to resting microglia, is associated with the
healing and maintenance of neural environment332–334. Clinical trials involving
inhibition of the immune system using NSAIDs and ibuprofen have yielded mixed
results and shown that a non-specific inflammatory blockade will most likely not
be a beneficial treatment for patients335–342. However, some evidence from these
studies does support the prevention and delay of symptoms associated with PD.
Therapeutic intervention targeting the phenotype shift between M1 and M2
microglia might be a more effective approach to treatment. Regulatory changes
in microglia induced by α-syn would be a novel and unique mechanism involved
in PD progression that could uncover new therapeutic targets and strategies.
This investigation focused on changes in DNA methylation and gene expression
induced by α-syn in microglia involved in shifting microglia to an M1 state.
Materials and Methods
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Study Design
This study is an ex vivo investigation of the effect of α-syn on
transcriptional regulation via methylation and gene expression levels in microglia.
Figure 13 outlines and describes the workflow of our study. Briefly, microglia
were isolated from 3- and 13-month-old mThy1-Asyn mice and wild type
littermate controls for DNA and RNA extraction. Reduced representation bisulfite
sequencing (RRBS) was used to identify methylation changes induced by α-syn
overexpression. RNA-sequencing was used to measure gene transcription levels
to assess the effect of methylation changes on transcription and expression
changes in response to α-syn stimulation.
Animals
Mice overexpressing full-length human wild-type α-syn under the murine Thy-1
promoter on the X chromosome were procured from the Chesselet laboratory at
the University of California, Los Angeles. The corresponding background of these
mice are the B6D2F1/J mice (stock# 100006) from The Jackson laboratory (Bar
Harbor, ME). In all performed studies, male animals were used in order to avoid
adverse effects produced by females’ ability to inactivate the X chromosome,
which may contain the inserted human α-syn gene under the m-Thy1 promoter.
The genotype of all mice was verified with PCR analysis of tail snip DNA via
general endpoint PCR.
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Figure 13. Study 3 Workflow and Description. mThy1-Asyn mice along with
littermate controls were aged to 3 and 13 months then euthanized for tissue
collection. Microglia were isolated from homogenized whole brains using a
percoll gradient. Both RNA and DNA were dually extracted, while the RNA was
used transcription sequencing and DNA underwent bisulfite conversion for
RRBS. Data were analyzed for DEGs and DMGs in order to identify possible
biomarkers. Gene lists were also analyzed for function enrichment using GO,
KEGG, and Reactome databases.
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The hypoxanthine guanine phosphoribosyl transferase (HPRT) gene was used
as the internal control with a forward primer of
GAAGAGCTACTGTAATGATCAGTCAACGG and a reverse primer of
GAGAGGTCCTTTTCACCAGCAAGC. The forward primer used for the human
SNCA gene was GCTACTGCTGTCACACCCGTC and the reverse primer was
GATGATGGCATGCAGCACTGG.
Animal Use
All procedures were approved by the University of North Dakota
Institutional Animal Care and Use Committee (UND IACUC) protocol 1506-2 ID
47. Mice were provided food and water ad libitum and housed in a 12-hour
light/dark cycle. The investigation conforms to the National Research Council of
the National Academies Guide for the Care and Use of Laboratory Animals (8th
edition)343.
Microglia Isolation
The protocol used for the isolation of adult mouse microglia was adapted
from Lee and Tansey 2013 in Methods Molecular Biology344. Briefly, freshly
perfused brains from euthanized mice were minced using a razor blade and
dissociated in medium containing 1mg/mL papin, DMEM, Dispase II (1.2
units/mL) and DNAse I (20 units/mL). After removing the dissociation medium,
the tissue was homogenized using various sized serological pipettes and then
filtered using a 40µm cell strainer. A percoll gradient of 30%, 37%, and 70%
percoll diluted with hank’s balanced salt solution (HBSS) was established with
homogenized tissue diluted into the 37% solution. The percoll gradient was
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centrifuged at 300xg for 40 minutes at 18C to separate microglia cells from other
tissue. The interphase containing the microglia was collected and washed three
times with HBSS to remove the remaining percoll. RLT plus buffer (Qiagen,
ID:80204) was added to the isolated microglia and this lysed solution was added
to QIAshredder homogenizer tubes (Qiagen ID:79654) and spun for 2 minutes at
maximum speed. The collection tube below the QIAshredder was then flash
frozen with liquid nitrogen and stored at -80C to preserve the solution for later
isolation of DNA and RNA.
Dual DNA/RNA Extraction and Isolation
The flash-frozen cells prepared during the microglia isolation protocol
were used with the Qiagen AllPrep DNA/RNA Mini Kit (Qiagen: 80204) to collect
the DNA and RNA from the microglia isolated from our wild type and mThy1Asyn mice. Our procedure followed the described Qiagen AllPrep protocol345.
Briefly, homogenized lysates were thawed and DNA was isolated from RNA via
spin column. RNA and DNA were purified using silica-membrane RNeasy and
AllPrep DNA spin columns. All RNA and DNA isolations from this preparation
were then frozen at -80C to be later used for a global methylation ELISA and
library preparations for sequencing.
Global Methylation Assay
Genomic DNA isolated from microglia preparations was quantified using
the Epoch microplate spectrophotometer (BioTek). The global DNA methylation
status of the microglial DNA from mThy1-Asyn and wild-type mice were
determined using the MethylFlash Global DNA Methylation (5-mC) ELISA Easy
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Kit (Epigentek: P-1030) according to Epigentek instructions. Briefly, 100ng of
genomic DNA was bound to each well. After washing, 5-methylcytosine detection
complex solution was added to each well and incubated for 50 minutes. Wells
were washed again, developer solution was added, and optical absorbance was
measured at 450nm. The percentage of methylated DNA was calculated based
on linear regression analysis.
Methylation Processing using Reduced Representation Bisulfite
Sequencing (RRBS)
This procedure for RRBS was adapted from Garrett-Bakelman et al346.
Briefly, Genomic DNA was extracted from our microglia isolation preparations as
per the methods described above. DNA quantity was a measured using a Qubit
fluorometer and quality was assessed using TapeStation (Agilent). Due to
sample limitations, a DNA integrity number (DIN) could not be used as a defined
cut off and sample selection for RRBS processing was based on quantity of DNA
where DINs were not measurable. Genomic DNA was digested with the Msp1
restriction enzyme and purified using phenol:chloroform extraction and ethanol
precipitation. Following Msp1 digestion, genomic DNA underwent blunt-end
digestion, phosphorylation, and ligation of adapters with methylated cytosines.
Ligated fragments were cleaned and processed for size selection on an agarose
gel. Selected fragments were bisulfite converted, amplified by PCR, and cleaned
using AMPure XP beads. The libraries were quantified using the Qubit assay and
Agilent’s High Sensitivity D1000 assay and sequenced on the Illumina Hi-Seq
4000 platform to generate raw sequence RRBS reads.
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Quality control assessment of RRBS data was completed using FastQC
version 0.11.5251. Raw Sequencing reads were cleaned using Trim Galore!
(version 0.5.0 Babraham Bioinformatics, UK) to remove reads with adapter
contamination and reads with a Phred quality score <30347. Trim Galore also has
a special setting for RRBS data that was utilized (--rrbs). Cleaned reads were
mapped to an in silico bisulfite converted mouse reference genome m38.p6Refseq using Bismark v0.20.0348 and Bowtie2 v2.3.4.2349. The R package
MethylKit v1.8.1350 was used to count uniquely mapped reads and assess
changes in methylation between wild-type and mThy1-Asyn mice at both our 3
month and 13 month time points. Differentially methylated CpGs (DMCs) were
defined as a 10% or greater difference in cytosine methylation levels between
wild-type and mThy1-Asyn mice with an adjusted p-value <0.01. Differentially
methylated genes (DMGs) were based on the total unique gene identifiers within
the list of DMCs. DMCs were annotated based on genes and CpG island
features using gene bodies and 2,5, and 10 kb regions upstream from
transcription start sites (TSSs) using the genomation351 R package. Annotation of
murine CpG islands were obtained from the University of California, Santa Cruz
(http://genome.ucsc.edu/ :GRCm38/mm10), and annotation of the murine genes
were obtained from Ensembl352 (http://www.ensembl.org) and Entrez353
(http://www.ncbi.nlm.nih.gov/Entrez/).
RNA-Sequencing Processing
Total RNA was obtained from isolated microglia preparations as per the
methods described in dual DNA/RNA extraction and isolation section above.
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RNA quality was evaluated using TapeStation (Agilent, Santa Clara, CA). Due to
sample limitations, a RNA integrity number of 5 was used as a cutoff for further
processing. These samples were processed using the NEBNext Ultra II RNA
Library Prep Kit (Catalog #E7770L/#E7775L) for Illumina. Resultant cDNA was
sequenced with a paired-end read length of 150 bases using and Illumina HiSeq
2000 by Novogene (https://en.novogene.com/).
Raw sequencing reads were cleaned using Trimmomatic to remove reads
with adapter or Poly-N sequences as well as reads with a quality score <30250.
Quality control assessment of RNA-Seq data was completed using the FastQC
version 0.11.5251. Cleaned reads were mapped to the mouse reference genome
m38.p6 Refseq using HISAT2252. FeatureCounts253 was used to count uniquely
mapped reads while genes with zero expression across samples were omitted
from differential expression analysis. Fragments per kilobase of exon per million
mapped reads (FPKM) as a measurement of transcript expression were
calculated using an in-house script. Differentially expressed genes (DEGs) were
identified using the DESeq2254 R package using a significance cut off of a <0.05
adjusted p-value (adj. p-value).
Enrichment and Network Analysis
Enrichment analysis of both DEGs and DMGs was conducted using our
in-house enrichment analysis R package RichR (http://github.com/hurlab/RichR).
Gene Ontology354 (GO), Kyoto Encyclopedia of Genes and Genomes354–356
(KEGG) and Reactome Pathway Database357,358 were used to identify enriched
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biological functions and pathways represented within our gene lists. An adjusted
p-value <0.05 was used as a significance cutoff.
The enrichment results using three different annotation databases were
combined and visualized in a network by RichR with enrichment terms as nodes
and shared gene contents of nodes indicated by edges. The top 20 (or less)
terms selected based on adjusted p-value from each annotation set were used in
network visualization. Cytoscape359 was used to visualize the network and
colorize nodes based on adjusted p-value. Within the network, node shape
indicates the annotation data each term is from. All networks were organized
using the inverted self-organizing map layout with minimal manual node
rearrangement for visibility.
Results
Microglia were isolated from the brains of mThy1-Asyn mice and their
littermate wild type controls to profile the DNA methylation patterns and gene
expression changes induced by the overexpression of α-synuclein. This model of
PD experiences changes in striatal dopamine levels, progressive motor and nonmotor symptoms, α-synuclein associated pathology, and inflammation similar to
what is observed in PD patients95,96. The time points (3 and 13 months) of tissue
collection were selected based on phenotypic changes observed in this model
associated with progressive symptoms and microglia associated inflammation.
Inflammatory markers can be observed as early as 1 month indicating early
stage neuroinflammation before mice become symptomatic360. Dopamine levels
rapidly decrease between 12 and 14 months and motor symptoms of PD become
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evident representing an early stage of PD similar to when patients become
symptomatic97,100,361. Methylation and gene expression profiles at these time
points offer unique insight into the initiation of neuroinflammation and progression
of PD symptoms associated with α-synuclein induces inflammation.
α-synuclein-Induced Methylation Changes in Microglia
Changes in methylation induced by α-synuclein overexpression were first
examined by quantifying global DNA methylation using the MethylFlash ELISA
which indicated an increase in methylation in the microglia from our transgenic
animals (Figure 14). These changes were further investigated using global
methylation patterns from RRBS of DNA isolated from microglia within the
mThy1-Asyn mouse. Quality assessment using FASTQC did not identify any
samples of low quality to be omitted from the study. Trim Galore was used for
quality and adapter trimming of reads to be passed to Bismarck and Bowtie2 for
alignment. The summary of prepared samples including number of reads
obtained (M seqs), duplicate sequences (% Dups), GC content (%GC),
percentage of reads trimmed (% Trimmed), and percentage of reads successfully
aligned (Bismarck Alignment %) can be found in Table 12. The R package
MethylKit assessed changes in methylation between transgenic and control mice
to determine DMCs based on a change in methylation (delta beta) and an
adjusted p-value<0.01. DMCs were annotated to CpG island features and
genetic regions in relation to the transcription start site of genes using the
genomation R package.
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Figure 14. Global DNA Methylation ELISA Results. Isolated DNA from 13month-old wild-type (n=3) and mThy1-Asyn (n=6) mice were also used in a
Global DNA methylation ELISA Easy kit from Epigentek. The results demonstrate
a significant increase in global 5-methylcytosine in the transgenic model’s DNA.
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DNA
RNA

Sample
Name

Bismarck
Alignment % Trimmed % Dups
%

% GC

Total
Reads
(millions)

13H01

67.70%

1.00%

89.50%

32%

125.2

13H02

64.90%

1.00%

89.00%

33%

113.9

13H03

65.00%

1.00%

87.40%

32%

104.9

13H04

64.10%

1.10%

88.30%

32%

143.1

13H05

66.60%

1.00%

87.20%

33%

125.2

13H06

65.30%

1.20%

87.60%

32%

103.6

13H07

61.30%

1.00%

90.40%

32%

176.6

13H08

64.20%

1.00%

86.80%

32%

110.2

13H09

NA

NA

NA

NA

NA

13H10

65.00%

1.10%

86.80%

32%

104.7

13W01
13W02

59.60%
40.60%

1.10%
1.10%

87.40%
88.40%

32%
33%

81.1
111.7

13W03

42.10%

1.00%

89.80%

33%

93

13W04

39.60%

0.90%

89.10%

32%

93.7

13W05

NA

NA

NA

NA

NA

13W06

NA

NA

NA

NA

NA

3H01

59.60%

1.10%

89.90%

32%

123.2

3H02

58.50%

1.00%

90.00%

32%

110.1

3H03

55.10%

1.00%

88.70%

33%

98.5

3H04

NA

NA

NA

NA

NA

3H05

45.90%

1.00%

89.50%

33%

127.1

3W01

63.40%

1.00%

90.30%

31%

146.4

3W02

54.00%

1.00%

87.30%

32%
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3W03

56.30%

1.00%

90.00%

31%

187.9

3W04

49.80%

1.10%

86.70%

32%

95.3

RNA Total
Reads
HISAT2
Reads
after
Alignment
(millions) trimming
%
43.0
44.2
93.26%
(97.25%)
46.9
48.2
93.20%
(97.31%)
43.8(95.17
46.1
91.99%
%)
NA
NA
NA
48.7
49.9
93.07%
(97.67%)
45.3
46.4
93.29%
(97.42%)
NA
NA
NA
54.6
55.9
92.77%
(97.64%)
68.4
70.0
91.88%
(97.71%)
67.4
68.8
93.01%
(97.91%)
NA
NA
NA
NA
NA
NA
61.4
62.9
94.32%
(97.63%)
80.3
82.0
94.50%
(97.88%)
68.6
70.3
94.34%
(97.65%)
85.0(97.88
86.9
94.05%
%)
55.9
57.2
94.78%
(97.73%)
NA
NA
NA
74.2
75.8
95.01%
(97.91%)
56.2
57.8
83.39%
(97.07%)
65.1
66.7
93.59%
(97.48%)
69.7
71.6
94.83%
(97.37%)
59.2
61.0
93.84%
(96.97%)
NA
NA
NA
55.3
57.2
93.64%
(96.72%)

Table 12. Sample Alignment Summary. Each mouse in both the 13- and 3month groups are listed on the left. Their inclusion in either RRBS (DNA) or RNAseq (RNA) is indicated by the blue and green coloring, respectively. The
assessment of each sample in terms of DNA included the millions of sequences
provided, percentage trimmed, and percentage of alignment using Bismarck
along with the percent of duplicated sequences and GC content. The RNA
assessment of each included sample includes the total reads, reads after
trimming, and the percentage of reads aligned using HISAT2.
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Microglial DNA harvested from our 3-month-old mice (4 wild type, 4
mThy1-Asyn) had 27,175 DMCs between transgenic and wild type mice based
on a minimum delta beta of 10% and an adjusted p-value<0.01. Across our
samples from 3-month animals, 1,234,490 total sites were measured with 11,441
significant CpGs showing an increase in methylation (hypermethylation) and
15,734 showing a decrease in methylation (hypomethylation). The delta beta for
the identified CpGs range from a 65% increase to a 72% decrease in
methylation. The top and bottom 20 DMCs, based on delta beta, and their
associated genes can be found in Tables 13 and 14. Based on the murine
annotation from University of California, Santa Cruz (UCSC), 6% of identified
CpGs can be found in CpG island regions and 8% in CpG shore regions (Figure
15A). These areas in relation to transcription start sights have been shown to
influence gene expression362,363. Annotation for promoter, exon, intron, and
intergenic gene regions were also used to evaluate and classify the DMCs
identified (Figure 15B). While 10% of DMCs were in promoter regions and 15%
located in exon regions of genes, the vast majority were found in intron (38%) or
intergenic regions (37%).
Multiple CpGs are assigned to the same genes in various locations on the
genome, which prevents any gene level determinations from this data without
further information. However, identifying all unique genes associated with the
DMCs provides a list of genes that could be influenced by methylation changes in
our model, or DMGs.
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EntrezID
84704
84704
84704
27412
20280
74387

Gene
Symbol
Snurf
Snurf
Snurf
Peg12
Scp2
4932438
H23Rik

SNRPN upstream reading frame
SNRPN upstream reading frame
SNRPN upstream reading frame
paternally expressed 12
sterol carrier protein 2, liver

65.35
64.27
61.71
54.90
48.33

Adj.
Pvalue
3.76E-69
3.41E-64
1.30E-59
3.96E-10
7.94E-54

RIKEN cDNA 4932438H23 gene

45.79

7.32E-47 chr16 , 91104256

Description

∆β

Gene Location
chr7 , 60005200
chr7 , 60005229
chr7 , 60005187
chr7 , 62464177
chr4 , 108136742

45.28

2.28E-34 chr16 , 14271833

57440
545677
56429
56280
57440
329015

myosin, heavy polypeptide 11,
smooth muscle
Ehd3
EH-domain containing 3
Gm12888 predicted gene 12888
Dpt
dermatopontin
Mrpl37
mitochondrial ribosomal protein L37
Ehd3
EH-domain containing 3
Atg2a
autophagy related 2A

44.59
42.79
41.64
41.01
40.17
39.02

4.15E-59
1.67E-55
7.64E-07
1.29E-18
1.82E-33
1.81E-43

20680

Sox7

38.63

2.41E-07 chr14 , 63942190

63913

Fam129a

38.22

5.55E-15 chr1 , 151621799

76422

Mroh3

38.02

1.22E-16 chr1 , 136162561

14538

Gcnt2

37.92

1.41E-04 chr13 , 40888061

252974

Tspear

37.23

1.01E-03 chr10 , 77664526

320772

Mdga2

MAM domain containing
glycosylphosphatidylinositol anchor 2

36.97

8.13E-14 chr12 , 66932444

12145

Cxcr5

chemokine (C-X-C motif) receptor 5

36.44

7.10E-27 chr9 , 44514115

17880

Myh11

SRY (sex determining region Y)-box 7
family with sequence similarity 129,
member A
maestro heat-like repeat family
member 3
glucosaminyl (N-acetyl) transferase 2,
I-branching enzyme
thrombospondin type laminin G
domain and EAR repeats

chr17 , 73823939
chr4 , 121355852
chr1 , 164823213
chr4 , 107013861
chr17 , 73820506
chr19 , 6248005

Table 13. Top 20 DMCs at 3 Months. Differentially methylated CpGs were
determined between wild type and mThy1-Asyn mice at 3 months of age and
paired with their gene annotation. The 20 CpGs with the greatest increase in
methylation (∆β) along with their associated gene annotation.
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EntrezID
26381
329540
16558
21873
66230
215303
17463
57278
18109
70881
68498
56748
26381
67755
13195
233081
20927
71517
217364
18314

Gene
Symbol
Esrrg
Nol4l
Kif16b
Tjp2
Mrps28

Description

∆β

estrogen-related receptor gamma
nucleolar protein 4-like
kinesin family member 16B
tight junction protein 2
mitochondrial ribosomal protein S28
calcium/calmodulin-dependent
Camk1g
protein kinase I gamma
proteasome (prosome, macropain)
Psmd7
26S subunit, non-ATPase, 7
Bcam
basal cell adhesion molecule
v-myc avian myelocytomatosis viral
Mycn
related oncogene, neuroblastoma
derived
Nt5c1b 5'-nucleotidase, cytosolic IB
Tspan11 tetraspanin 11
Nfu1
NFU1 iron-sulfur cluster scaffold
Esrrg
estrogen-related receptor gamma
DEAD (Asp-Glu-Ala-Asp) box
Ddx47
polypeptide 47
Ddc
dopa decarboxylase
Ffar1
free fatty acid receptor 1
ATP-binding cassette, sub-family C
Abcc8
(CFTR/MRP), member 8
9030624
RIKEN cDNA 9030624J02 gene
J02Rik
Engase endo-beta-N-acetylglucosaminidase
Olfr17
olfactory receptor 17

-72.17
-61.77
-53.81
-48.50
-46.97

Adj.
Pvalue
2.98E-38
1.27E-51
7.96E-61
4.79E-17
1.12E-09

Gene Location
chr1 , 187630622
chr2 , 153422452
chr2 , 142788388
chr19 , 24216202
chr3 , 8894548

-46.30 1.93E-50 chr1 , 193384944
-43.77 3.17E-32 chr8 , 108009687
-43.56 7.56E-12 chr7 , 19767561
-41.28 7.48E-28 chr12 , 12694576
-40.61
-40.46
-39.54
-39.52

7.38E-18
2.17E-70
1.19E-15
2.01E-39

chr12 , 10242598
chr6 , 127866059
chr6 , 86949756
chr1 , 187630781

-39.21 4.23E-26 chr6 , 135035635
-38.89 6.88E-08 chr11 , 11822370
-37.80 2.03E-07 chr7 , 30866410
-37.62 1.80E-09 chr7 , 46178186
-37.44 1.68E-47 chr7 , 118773890
-37.38 1.71E-07 chr11 , 118487128
-37.21 5.91E-08 chr7 , 107085773

Table 14. Bottom 20 DMCs at 3 Months. Differentially methylated CpGs were
determined between wild type and mThy1-Asyn mice at 3 months of age and
paired with their gene annotation. The 20 genes that demonstrate the greatest
decrease in methylation (∆β) along with their associated gene annotation.
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A

B

Figure 15. Genomic Regions of 3 Month DMCs. DMCs were identified from
our 3-month animals through RRBS. (A) The DMCs identified composed of 6 %
island and 8% shore CpG regions. (B) The majority of DMCs are intergenic or
located in the intron of genes with only 10% found in the promoter regions.
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These DMCs are located in genomic locations associated with 5,315 unique
DMGs. The list of DMGs from our 3-month-old mice were used for functional
analysis with an in-house R package RichR. Enriched biological functions and
pathways represented within our gene list were identified which consisted of
1904 GO terms, 115 Reactome Pathways, and 26 KEGG functions based on a
significance cutoff of adjusted p-value <0.05. The top 20 enriched terms from
each database based on adjusted p-value were merged together for network
analysis. The network of associated terms was created using RichR with
enriched terms serving as nodes and shared DEGs forming edges between
nodes (Figure 16). Visualization of the network was executed using Cytoscape to
color nodes based on an adjusted p-value scale and to change node shape
based on their annotation database. All GO terms are circular nodes, KEGG
terms are represented by triangle nodes, and Reactome pathways have diamond
nodes. Network layout was minimally adjusted for visibility from the inverted selforganized map layout from Cytoscape. Subnetworks of nodes related to neuronal
development, synaptic transmission, intracellular signaling, and
adhesion/migration can all be identified within the network.
Similarly, microglial DNA was harvested from 13-month-old mice (4 wild
type, 9 mThy1-Asyn) for methylation profiling. Although our later 13-month
animals exhibit a more severe phenotype, there were less DMCs identified in 13month than in the previous 3-month group. Across our samples from 13-month
animals, 1,151,250 total sites were measured, with 10,436 DMCs being
hypermethylated and 4,790 DMCs hypomethylated. The older mice had 15,226
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Figure 16. Enrichment Network from 3 Month DMCs. DMCs were focused to a gene level and used for enrichment
analysis through GO (circle), KEGG (triangle), and Reactome (diamond). Top 20 adjusted p-value enrichment terms from
each list make up the nodes of the network while shared genes between terms are represented by the edges. Node color
correlates to adjusted p-value. Network layout is from the Cytoscape inverted self-organized map layout.
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DMCs, which were annotated to 3,742 genes (DMGs) using a 10% change in
methylation as a minimum and a cutoff of an adjusted p value <0.01. The DMCs
identified had a delta beta range from a 43% increase to a 55% decrease in
methylation. The top and bottom 20 DMCs, based on delta beta, and their
associated genes can be found in Tables 15 and 16. From the DMCs identified,
5% are found in CpG islands with another 9% in CpG shores (Figure 17A).
Similar to our 3-month group, the majority of DMCs are located in intron (41%)
and intergenic regions (35%) while 10% were located in promoters and 15% in
exons (Figure 17B).
The DMG list from our 13-month mice were also assessed for enrichment
of biological functions and pathways from GO (1782 terms), Reactome Pathway
(106 pathways), and KEGG (54 functions) databases. An adjusted p-value<0.05
was used as a cutoff in determining if a term was significantly enriched. The top
20 enriched terms based on adjusted p-value were selected to be used for
network analysis to further identify thematic clusters within the data (Figure 18).
Network files were generated with RichR files while Cytoscape was used to
visualize the network with node shapes corresponding to a terms database and
color indicating the adjusted p-value. Cytoscape’s inverted self-organized map
layout was used to organize the network with slight manual adjustments for
visibility. Terms related to adhesion and locomotion are the most common within
the network. The largest cluster of highly connected terms is largely related to
proliferation and development, such as neurogenesis, generation of neurons,
regulation of cell process, and neuronal differentiation.
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14873
71972
74287
12306

Gene
Symbol
Gsto1
Dnmbp
Kcmf1
Anxa2

93685

Entpd7

217837

Itpk1
A43003
3K04Rik
Fut10
Epas1
Ablim1
Sec31b

EntrezID

243308
171167
13819
226251
240667
20361
105782
56280
53626
15445
140703
101434
12306
14683

Description

43.06
39.50
39.01
38.21

Adj.
Pvalue
1.26E-47
2.26E-30
1.03E-17
4.99E-11

37.45

1.91E-10 chr19 , 43706608

36.85

4.88E-11 chr12 , 102706751

36.12

4.62E-22 chr5 , 138647371

35.43
34.85
34.34
33.51

1.58E-30
1.17E-08
1.47E-12
5.97E-49

33.39

1.19E-06 chr9 , 57954086

33.35
33.26
32.91
32.88
32.69

1.21E-07
7.34E-10
8.51E-04
5.22E-18
1.33E-06

32.65

5.68E-04 chr7 , 16670321

32.47

6.57E-08 chr9 , 69518031

32.34

4.07E-04 chr2 , 174326956

∆β

glutathione S-transferase omega 1
dynamin binding protein
potassium channel modulatory factor 1
annexin A2
ectonucleoside triphosphate
diphosphohydrolase 7
inositol 1,3,4-triphosphate 5/6 kinase
RIKEN cDNA A430033K04 gene

fucosyltransferase 10
endothelial PAS domain protein 1
actin-binding LIM protein 1
Sec31 homolog B (S. cerevisiae)
sema domain, immunoglobulin domain
Sema7a (Ig), and GPI membrane anchor,
(semaphorin) 7A
Scrib
scribbled planar cell polarity
Mrpl37 mitochondrial ribosomal protein L37
Insm1
insulinoma-associated 1
Hpd
4-hydroxyphenylpyruvic acid dioxygenase
Emid1
EMI domain containing 1
Ceacam carcinoembryonic antigen-related cell
15
adhesion molecule 15
Anxa2
annexin A2
GNAS (guanine nucleotide binding
Gnas
protein, alpha stimulating) complex locus

Gene Location
chr19 , 47856960
chr19 , 43901230
chr6 , 72869748
chr9 , 69517991

chr8 , 31262370
chr17 , 86786799
chr19 , 57238326
chr19 , 44531201

chr15 , 76059286
chr4 , 107056075
chr2 , 146184015
chr5 , 123197372
chr11 , 5139618

Table 15. Top 20 DMCs at 13 Months. Differentially methylated CpGs were
determined between wild type and mThy1-Asyn mice at 13 months of age and
paired with their gene annotation. The 20 CpGs with the greatest increase in
methylation (∆β) along with their associated gene annotation.
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EntrezID
68243
17076
68243
75051
68243
68243
21838
68243
329421
241556
22174
21838
19089
21838
21938
56369
74194
387511
71918
54120

Gene
Symbol
A930018
P22Rik
Ly75
A930018
P22Rik
Ccdc173
A930018
P22Rik
A930018
P22Rik
Thy1
A930018
P22Rik
Myo3b
Tspan18
Tyro3
Thy1
Prkcsh
Thy1

Description

∆β

Adj.
Pvalue

Gene Location

RIKEN cDNA A930018P22 gene

-55.44 2.36E-28 chr2 , 104167970

lymphocyte antigen 75

-54.50 4.25E-70 chr2 , 60396648

RIKEN cDNA A930018P22 gene

-47.07 3.18E-32 chr2 , 104167969

coiled-coil domain containing 173

-45.94 3.79E-47 chr2 , 69766312

RIKEN cDNA A930018P22 gene

-44.71 4.26E-82 chr2 , 104168099

RIKEN cDNA A930018P22 gene

-44.48 7.73E-83 chr2 , 104168129

thymus cell antigen 1, theta

-44.12 1.85E-30 chr9 , 44049625

RIKEN cDNA A930018P22 gene

-42.83 6.73E-56 chr2 , 104168158

myosin IIIB
tetraspanin 18
TYRO3 protein tyrosine kinase 3
thymus cell antigen 1, theta
protein kinase C substrate 80K-H
thymus cell antigen 1, theta
tumor necrosis factor receptor
Tnfrsf1b
superfamily, member 1b
Apip
APAF1 interacting protein
Rnd3
Rho family GTPase 3
Tas2r134 taste receptor, type 2, member 134
Zcchc24 zinc finger, CCHC domain containing 24
GIPC PDZ domain containing family,
Gipc2
member 2

-40.23
-39.35
-39.26
-37.36
-37.29
-36.96

1.54E-16
1.96E-64
7.53E-23
8.57E-16
4.20E-06
9.69E-20

chr2 , 70149298
chr2 , 93351814
chr2 , 119805409
chr9 , 44049669
chr9 , 22015846
chr9 , 44049598

-36.15 1.56E-10 chr4 , 145222523
-36.03
-35.64
-35.58
-35.13

7.26E-26
4.17E-22
7.20E-58
3.10E-06

chr2 , 103112082
chr2 , 51076402
chr2 , 51667495
chr14 , 25780948

-35.08 3.81E-06 chr3 , 152092787

Table 16. Bottom 20 DMCs at 13 Months. Differentially methylated CpGs were
determined between wild type and mThy1-Asyn mice at 13 months of age and
paired with their gene annotation. The 20 genes that demonstrate the greatest
decrease in methylation (∆β) along with their associated gene annotation.
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A

B

Figure 17. Genomic Regions of 13-Month DMCs. DMCs were identified from
our 13-month animals through RRBS. (A) The DMCs identified in the 13-month
comparison were composed of 5% CpG islands. (B) The majority of DMCs were
in intron or intergenic regions but 10% were from promoter regions of genes. The
list of DMCs were focused down to gene level and used for enrichment analysis.
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Figure 18. Enrichment Network from 13-Month DMCs. The top 20 adjusted p-value terms from GO (circle), KEGG
(triangle), and Reactome (diamond) represent the nodes and shared genes between term annotations form the edges.
Node color is based on adjusted p-value and the network layout is adjusted from the Cytocape inverted self-organized
map for visibility.
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The subnetwork related to cell surface interactions with terms such as focal
adhesion, integrin cell surface interactions, extracellular matrix, and collagen
chain trimerization is connected to platelet-derived growth factor (PDGF) and
receptor tyrosine kinase signaling (RTK). PDGF and RTK have been shown to
induce proliferation in glial cells364–366.
α-synuclein-induced Gene Expression Changes in Microglia
Gene expression changes induced by α-synuclein overexpression were
measured in microglia isolated from wild type and mThy1-Asyn mice using RNAsequencing. Adapter and low-quality reads were trimmed before alignment using
Trimmomatic. The quality of data obtained from sequencing was assessed using
FastQC, which did not identify any samples for exclusion based on read quality.
HISAT2 aligned cleaned reads to the mouse reference genome and DESeq2
determined DEGs based on read counts using an adjusted p-value <0.05 as a
cutoff. The summary, including reads obtained, reads after trimming, and
percentage of reads aligned for each sample, can be found in Table 12.
Microglial RNA harvested from 3-month-old wild-type (n=3) and mThy1Asyn (n=4) mice had 119 DEGs based on an adjusted p-value cutoff of <0.05.
The top and bottom 20 DEGs based on log2 fold change (log2FC) are available
in Tables 17 and 18. Some of the most upregulated genes include chemokines
such as Ccl1 and Ccl17. The complete DEG list was investigated for functional
terms and pathways represent in our gene lists based on annotation from GO (38
terms), Reactome pathways (3 pathways), and KEGG (3 functions) databases
and an
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EntrezID Gene Symbol
76237
105349
235379
20290
12919
12823
66673
21838
16161
15561
320429
20303
15563
14810
20295
319942
14417
242773
67331
72978

Description

6430628N08Rik RIKEN cDNA 6430628N08 gene
aldo-keto reductase family 1, member
Akr1c18
C18
Gldn
gliomedin
Ccl1
chemokine (C-C motif) ligand 1
corticotropin releasing hormone
Crhbp
binding protein
Col19a1
collagen, type XIX, alpha 1
sortilin-related VPS10 domain
Sorcs3
containing receptor 3
Thy1
thymus cell antigen 1, theta
Il12rb1
interleukin 12 receptor, beta 1
5-hydroxytryptamine (serotonin)
Htr3a
receptor 3A
tetratricopeptide repeat and ankyrin
Trank1
repeat containing 1
Ccl4
chemokine (C-C motif) ligand 4
5-hydroxytryptamine (serotonin)
Htr5a
receptor 5A
glutamate receptor, ionotropic, NMDA1
Grin1
(zeta 1)
Ccl17
chemokine (C-C motif) ligand 17
A530016L24Rik RIKEN cDNA A530016L24 gene
Gad2
glutamic acid decarboxylase 2
Slc45a1
solute carrier family 45, member 1
Atp8b3
ATPase, class I, type 8B, member 3
cornichon family AMPA receptor
Cnih3
auxiliary protein 3

Adj.
log2FC
Pvalue
0.01
6.31
0.03

6.04

0.00
0.03

3.38
3.02

0.00

2.66

0.05

2.26

0.03

2.00

0.01
0.01

1.89
1.87

0.04

1.80

0.03

1.78

0.01

1.74

0.03

1.72

0.03

1.70

0.02
0.02
0.02
0.04
0.03

1.69
1.63
1.62
1.60
1.59

0.04

1.55

Table 17. 20 most up-regulated DEGs at 3 Months. Differentially expressed
genes were determined between wild type and mThy1-Asyn mice at 3 months of
age. The 20 genes with the greatest increase in expression are presented in this
table.
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EntrezID
13861
16521
76615
53856
68509
22262
229277
403180
67747
75573
381522
53873
66758
213248
434756
320159
74338
381284
56087
110082

Gene
Adj.
Description
log2FC
Symbol
Pvalue
Epx
eosinophil peroxidase
0.00
-2.51
potassium inwardly-rectifying
Kcnj5
0.01
-2.47
channel, subfamily J, member 5
glutamic-oxaloacetic transaminase 1Got1l1
0.00
-2.20
like 1
Prg3
proteoglycan 3
0.05
-2.17
Ptx4
pentraxin 4
0.01
-2.16
Uox
urate oxidase
0.02
-2.12
Stoml3
stomatin (Epb7.2)-like 3
0.02
-2.05
Ccdc121 coiled-coil domain containing 121
0.02
-2.04
Ribc2
RIB43A domain with coiled-coils 2
0.00
-2.03
Prr29
proline rich 29
0.02
-2.00
Ccdc180 coiled-coil domain containing 180
0.00
-1.97
eosinophil-associated, ribonuclease
0.02
-1.76
Ear6
A family, member 6
Zfp474
zinc finger protein 474
0.02
-1.75
Wdr49
WD repeat domain 49
0.05
-1.75
Akap14
A kinase (PRKA) anchor protein 14
0.03
-1.74
family with sequence similarity 179,
Fam179a
0.02
-1.69
member A
solute carrier family 6
Slc6a19 (neurotransmitter transporter),
0.02
-1.66
member 19
ciliary rootlet coiled-coil, rootletin
Crocc2
0.02
-1.63
family member 2
Dnah10
dynein, axonemal, heavy chain 10
0.01
-1.63
Dnah5
dynein, axonemal, heavy chain 5
0.02
-1.63

Table 18. 20 most down regulated DEGs at 3 Months. Differentially expressed
genes were determined between wild type and mThy1-Asyn mice at 3 months of
age. The 20 genes that demonstrate the greatest decrease in expression are
presented in this table.
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adj. p-value <0.05. RichR performed enrichment analysis and constructed a
network using the top 20 terms from GO (adj. p-value) and the full lists of
enrichment terms from KEGG and Reactome (Figure 19). The network file was
visualized using Cytoscape with an inverted self-organized map layout which was
manually adjusted for visibility.
The more severe phenotype associated with the older (13 month) mice
used in our study was reflected by the higher number of DEGs identified between
wild type (n=5) and mThy1-Asyn (n=8) mice. RNA harvested from isolated
microglia in these older animals identified 3,766 DEGs using an adjusted p-value
cutoff of <0.05. The top and bottom 20 DEGs based on log2 fold change (FC) are
shown in Tables 19 and 20. RichR was used to determine functional enrichment
terms and pathways represented within the DEG list. Overall 1,509 GO terms,
230 Reactome pathways, and 35 KEGG functions were determined to be
enriched within our dataset. The top 50 enriched terms from GO enrichment
based on adjusted p-value can be found in Figure 20. Many of the GO terms are
related to development, migration, and adhesion.
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Figure 19. Enrichment Network from 3-Month DEGs. The differentially expressed genes from the 3-month analysis
were assessed for enrichment of biological functions and pathways using the GO (circle), KEGG (triangle), and Reactome
(diamond) databases. The top 20 (adj. p-value) enrichment terms from each database serve as the network nodes and
the shared genes between term annotations serve as the edges connecting them. Node shape is based on the terms
database (see above), while color represents the adjusted p-value score of each term. The network layout is adjusted
from Cytoscape’s inverted self-organized map for visibility.
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EntrezID

Gene
Symbol

NA

Igkv8-34

15891

Ibsp

NA

Ighg1

380683
24108
22431
192188
15378

Sec14l3
Ubd
Wt1
Stab2
Hnf4a

NA
50701
53873
16833
442829
619288
170813
19074
13861
17523
13035
19152

Description

Adj.
log2FC
Pvalue

immunoglobulin kappa variable
0.0329
8-34
integrin binding sialoprotein
0.0004
immunoglobulin heavy constant
0.0007
gamma 1 (G1m marker)

SEC14-like lipid binding 3
ubiquitin D
Wilms tumor 1 homolog
stabilin 2
hepatic nuclear factor 4, alpha
T cell receptor alpha variable
Trav12-3
12-3
Elane
elastase, neutrophil expressed
eosinophil-associated,
Ear6
ribonuclease A family, member
6
Ldhc
lactate dehydrogenase C
Ccin
calicin
family with sequence similarity
Fam71a
71, member A
membrane-spanning 4Ms4a3 domains, subfamily A, member
3
Prg2
proteoglycan 2, bone marrow
Epx
eosinophil peroxidase
Mpo
myeloperoxidase
Ctsg
cathepsin G
Prtn3
proteinase 3

6.76
5.75
5.69

0.0020
0.0419
0.0075
0.0002
0.0411

5.07
4.68
4.34
4.28
4.23

0.0077

4.19

0.0000

4.02

0.0000

3.81

0.0010
0.0396

3.80
3.80

0.0304

3.78

0.0000

3.67

0.0005
0.0002
0.0000
0.0000
0.0001

3.66
3.66
3.64
3.39
3.36

Table 19. 20 most up regulated DEGs at 13 Months. Differentially expressed
genes were determined between wild type and mThy1-Asyn mice at 13 months
of age. The 20 genes with the greatest increase in expression are presented in
this table.
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EntrezID
75512
56184
74556
380780

Gene
Description
Symbol
Gpx6
glutathione peroxidase 6
Msgn1
mesogenin 1
thymocyte selection associated family
Themis3
member 3
serine (or cysteine) peptidase inhibitor,
Serpina11 clade A (alpha-1 antiproteinase, antitrypsin),
member 11

0.0199

-2.01

0.0049

-1.97

potassium channel, subfamily K, member 18 0.0000

-1.84

332396

Kcnk18

NA
259114
234724

Gm10570 predicted gene 10570
Olfr570
olfactory receptor 570
Tat
tyrosine aminotransferase
opsin 1 (cone pigments), medium-waveOpn1mw
sensitive (color blindness, deutan)
Gpr50
G-protein-coupled receptor 50
Esrrb
estrogen related receptor, beta
Calml4
calmodulin-like 4
sulfotransferase family, cytosolic, 1C,
Sult1c2
member 2
Prr32
proline rich 32
Dlx3
distal-less homeobox 3
Gsc
goosecoid homeobox
Cox8b
cytochrome c oxidase subunit VIIIb
Grhl3
grainyhead-like 3
Oc90
otoconin 90
ventricular zone expressed PH domainVeph1
containing 1

14539
14765
26380
75600
69083
68800
13393
14836
12869
230824
18256
72789

Adj.
log2FC
Pvalue
0.0015 -4.21
0.0303 -2.05

0.0065
0.0180
0.0038

-1.76
-1.75
-1.51

0.0484

-1.50

0.0486
0.0000
0.0000

-1.49
-1.48
-1.38

0.0197

-1.37

0.0003
0.0162
0.0023
0.0005
0.0000
0.0029

-1.35
-1.34
-1.32
-1.32
-1.31
-1.30

0.0182

-1.30

Table 20. 20 most down regulated DEGs at 13 Months. Differentially
expressed genes were determined between wild type and mThy1-Asyn mice at
13 months of age. The 20 genes that demonstrate the greatest decrease in
expression are presented in this table.
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Figure 20. GO Enrichment in 13-Month DEGs. DEGs identified from the 13month comparison were analyzed for enrichment in terms of GO annotation. The
top 50 most significantly enriched terms are listed. Dot size corresponds to the
number of genes in each group, while color represent the significance level of
enrichment. Rich factor indicates the ratio of genes submitted to the number of
genes annotated to a function or pathway as an addition measure of enrichment.
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The top 50 most enriched KEGG pathways (Figure 21) includes terms
involved with various cancer pathways along with immune and adhesion related
functions. While Reactome pathways identified enriched pathways related to cell
cycle, immune system, and mitochondrial dysfunction (Figure 22). Network
analysis through RichR and Cytoscape were used to visualize associations
between terms based on common genes (Figure 23). A clear subnetwork
associated with cell cycle and mitosis can be seen and a smaller subnetwork
related to immune system function is also present. The largest subnetwork
includes many terms involved in cellular metabolism, which share edges with
neuroinflammatory conditions such as Parkinson’s, Alzheimer’s, and
Huntington’s disease.
Potential DEGs related to the progression of the mTHy1-Asyn phenotype
were investigated by examining both 3- and 13-month DEG lists for shared
genes. Table 21 shows the 9 shared genes between the two groups. Out of the 9
shared genes, 4 appear to be directionally discordant while the other 5 are
concordant between groups. The genes demonstrating a decrease in expression
at 3 months but increased expression at 13 include Epx, Prg3, and Ear6. The
only other discordant gene is Stra6, which has increased expression at 3 months
and decreased at 13 months. All other genes display an increase in expression
levels at both time points. These genes, including Zfp683, Il12rb1, Ccl4, Ccl3,
and Ccrl2, are related to a proinflammatory status involving macrophage
inflammatory proteins.
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Figure 21. KEGG Enrichment in 13 Month DEGs. DEGs identified from the 13month comparison were analyzed for enrichment in terms of KEGG annotation.
The top 50 most significant terms are listed. Dot size corresponds to the number
of genes in each group, while color represent the significance level of
enrichment. Rich factor indicates the ratio of genes submitted to the number of
genes annotated to a function or pathway as an addition measure of enrichment.
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Figure 22. Reactome Pathway Enrichment in 13 Month DEGs. DEGs identified from the 13-month comparison were
analyzed in terms of Reactome annotation. The top 50 most significant pathways are listed. Dot size corresponds to the
number of genes in each group, while color represent the significance level of enrichment. Rich factor indicates the ratio
of genes submitted to the number of genes annotated to a function or pathway as an addition measure of enrichment.
116

Figure 23. Enrichment Network from 13 Month DEGs. The differentially expressed genes from the 13-month analysis
were assessed for enrichment of biological functions and pathways using the GO (circle), KEGG (triangle), and Reactome
(diamond) databases. The top 20 (adj. p-value) enrichment terms from each database serve as the network nodes and
the shared genes between term annotations serve as the edges connecting them. Node shape is based on the terms
database (see above) while color represents the adjusted p-value score of each term. The network layout is adjusted from
Cytoscape’s inverted self-organized map for visibility.
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Gene
Symbol

Description

Zfp683

zinc finger protein 683

Stra6
Il12rb1

stimulated by retinoic acid gene 6
interleukin 12 receptor, beta 1

Ccl4
Ccrl2

chemokine (C-C motif) ligand 4
chemokine (C-C motif) receptor-like 2

Epx
Ccl3

eosinophil peroxidase
chemokine (C-C motif) ligand 3

Prg3

proteoglycan 3
eosinophil-associated, ribonuclease A
family, member 6

Ear6

13
3 Month
Month
Log2FC
Log2FC

1.53
-0.50
1.05
2.39
1.91
3.66
1.91
3.20

1.62
0.62
1.87
1.74
1.44
-2.51
1.29
-2.17

3.81

-1.76

Table 21. DEGs shared between 3- and 13-Month Groups. Nine genes were
found to be differentially expressed at both time points within this study. The
gene symbols are on the left, followed by a description and the log2FC values in
13- and 3-month comparisons. The color gradient indicates an increase (red) or
decrease (blue) in log2FC. Out of the 9 common DEGs, 5 are concordant while 4
are discordant between groups.
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Correlation between Identified DMGs and DEGs
Changes in DNA methylation are often thought to influence gene
expression levels based on CpG location in relation to the gene and transcription
start sight. Possible correlations between changes in methylation and changes in
expression between identified DMGs and DEGs were investigated and the
results are summarized in Figure 24A. DMCs were separated into their annotated
regions such as CpG islands and shores as well as gene promoter, intron, exon,
and intergenic regions. Gene names for each DMC belonging to these groups
were obtained from the UCSC annotation and matched to their corresponding
DEGs. The overlap between DMCs related genes and DEGs ranged from 1 to
320 shared genes. Pearson correlation tests were used to determine correlation
coefficients. Each DMC with gene annotation matching identified DEGs were
used in the Pearson correlation calculation. When one gene had multiple DMCs,
the expression value obtained during DEG analysis was counted multiple times
for each DMC. All five genomic regions of interest were examined for correlation
but only intronic DMCs in 13-month-old animals had a significant slightly negative
correlation (r=-0.15, p=0.008) between delta beta and fold change (Figure 24B).
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A

B

DataSet
13 Month
DEGs
DMCs

3766
15226

DMGs

3742

3 Month
DEGs
DMCs

119
27175

DMGs

5315

Annotation
Island
Shore
Promoter
Exon
Intron
Island
Shore
Promoter
Exon
Intron

CpGs
310
536
590
1157
2817
888
1283
1602
3046
6789

Genes
121
358
373
673
1442
329
834
961
1607
3033

Shared RNA Pearson
1
NA
66
-0.05
65
-0.2
120
-0.002
320
-0.15
2
-1
3
0.56
8
-0.33
10
-0.144
28
0.07

Pearson P
NA
0.7
0.11
0.98
0.008
NA
0.67
0.42
0.69
0.74

Figure 24. Correlation Summary of Genes Both Differentially Methylated and Expressed. Genomic and CpG
associated regions for the identified DMCs from both comparisons were assessed for their correlation with measured
gene expression from RNA-sequencing. (A) The summary table of DMC annotation shows the total amount of DMCs
identified and how many DMGs are represented in that list along with the associated DEGs identified. DMCs that belong
to genomic promoter, exon, or intronic regions or from CpG associated island or shore regions were used to assess the
correlation between methylation and gene expression changes. (B) The only region which showed a significant correlation
was the intronic region in the 13-month dataset.
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Discussion
This study examined regulation of the immune response in the central
nervous system by examining changes related to genomic methylation and gene
expression in microglia from the mThy1-Asyn mouse model of PD. This model
overexpresses human wild-type α-syn and exhibits a neuroinflammatory
phenotype with progressive PD like symptoms96. RRBS and RNA-seq were used
to measure methylation and gene expression changes at 3 and 13 months of
age. These time points were selected based on phenotypic changes associated
with a pre-parkinsonian phenotype at 3 months and an early stage symptomatic
phenotype with a decrease of striatal dopamine occurring at 14 months96–98,361.
This study provides a unique opportunity to identify changes induced by
aggregate and oligomerized α-syn on microglia, which are largely responsible for
the neuroinflammation associated with PD367.
The examination of changes induced in our early stage mice at 3 months
identified a wide variety of changes in methylation and relatively few in gene
expression. Overall, 11,441 DMCs were identified from the microglia of our
transgenic mice at 3 months with 6% positioned within CpG islands and 10% in
promoter regions. The genes which were annotated to the DMCs identified were
associated with neuronal development, synaptic transmission, intracellular
signaling, adhesion, and migration functions based on enrichment analysis using
GO, Reactome pathways, and KEGG databases. Microglia are highly involved in
the regulation of synaptic activity and have been shown to be the major players
in synaptic pruning368. The enrichment of these pathways may suggest a shift
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from a resting phenotype, involved in maintaining neuronal homeostasis, to an
active inflammatory state requiring mobility. Gene expression data from these
mice also reflect this possible shift in phenotype. We identified 119 DEGs when
comparing transgenic to wild-type controls. Some of the most upregulated genes
include Ccl1 which is a chemokine that attracts immune cells and Ccl17 which
induces chemotaxis, both are indicative of a proinflammatory response.
Enrichment analysis of the complete list of 119 DEGs using GO, Reactome, and
KEGG, identified biological functions involved in immune function and cellular
movement represented by our gene list. Both methylation and expression
changes were annotated to similar functional terms; however, no significant
correlations between DMC locations and gene expression were identified within
our 3-month animals.
Changes induced in methylation and gene expression in 13-month-old
animals reflect a more severe phenotype representing the early stages of
Parkinson’s symptoms. Examination of global genome methylation patterns
identified 10,436 DMCs of which 5% were located within CpG islands and 10% in
promoter regions. When focused to a gene level based on gene annotation for
each CpG, these DMCs represent 3,742 DMGs. Enrichment analysis on this list
of DMGs revealed function terms involving cell locomotion, adhesion, and
development. Network analysis of these terms identified a subnetwork of
interconnected terms involving cell surface interactions, adhesion, and
extracellular matrix with platelet derived growth factor signaling (PDGF) and
receptor tyrosine kinases (RTK). Both PDGF and RTK signaling have been
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shown to be strong inducers of proliferation364,366 and our DMG enrichment
network exhibits a wide variety of terms indicative of proliferation (Figure 18).
Increased mobility and proliferation of microglia has been linked to
neurodegeneration369. Gene expression changes in these animals represent
similar functions to that identified in the methylation analysis.
Overall, 3,766 DEGs were identified and examined for functional
enrichment as well. Gene ontology identified adhesion and migration functions
that were enriched, KEGG results indicate involvement of the immune system,
and Reactome pathways represented in the data are highly related to
metabolism and the immune system. However, all three annotation databases
represented an abundance of terms reflecting proliferation. Network analysis
examining the top 20 enriched terms from each annotation database also
provided insight into how these systems interact. While proliferation and cell
cycle terms were present throughout this analysis, in the network they form an
isolated cluster. This may not mean that these functions are not related to other
themes observed in the data such as metabolism and immune function since our
network analysis is limited to gene overlap and is non-directional. Another small
cluster of terms related to immune involvement is also isolated from the main
body of the generated network. The main subnetwork is composed of terms
related to metabolism that have shared edges with neurodegenerative conditions
such as Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease.
Terms relating to mitochondrial dysfunction, which is often proposed as a
causative factor in neurodegenerative diseases24,57,370–372, were also identified in
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this data. In our network analysis, while some mitochondria terms are
disconnected islands, others involved in cellular respiration were directly linked to
disease terms. The data representing our early stage PD animals indicate that
activated microglia are subjected to the mitochondrial stress associated with
exposure to aberrant α-syn371,373,374.
Correlations between identified methylation changes and gene expression
changes were investigated for DMCs located in CpG Islands, CpG shores,
promoters, exons, and introns. The only significant correlation between the data
was identified from DMCs in intronic regions which had a negative correlation
with gene expression (r=-0.15, p=0.008). Furthermore, overlap between 3- and
13-month animals were also evaluated for genes related to progression of the
disease. Comparing DEG lists resulted in 9 genes that were represented in both
datasets from the comparison between wild type and transgenic mice. Of those 9
genes, 5 showed an increase in expression in both datasets while the other 4
genes were directionally discordant going up in one group and down in the other.
Three of the concordant genes are immune related (Ccl4, Ccrl2, and Il12rb1) and
involved in immune recruitment and chemotaxis375. All but one of the genes that
change during the progression of the disease from 3 to 13 months have a
lowered expression level at 3 months and are over expressed at 13 months.
These genes include eosinophil peroxidase (Epx), proteoglycan3 (Prg3) and
eosinophil-associated, ribonuclease A family member 6 (Ear6).
Epx has been linked to the serpine superfamily of proteins which
commonly serve as protease inhibitors controlling proteolytic cascades376–379.
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Serpineb9 which is a cysteine protease is slightly upregulated at 13 months in
our data (data not shown) and not significantly different at 3 months. Cysteine
proteases are important for microglia as they are critical for accelerated collagen
and elastin degradation at sites of inflammation and play a role in MHC class II
immune response, apoptosis, and extracellular matrix remodelling370,380. One of
the enriched functions in the 13-month DMCs was collagen chain trimerization
which was connected to cell surface interactions, extracellular matrix
organization, focal adhesion, signaling by RTK and PDGF signaling. The
evidence for this cascade from Epx expressions levels and interactions are not
direct and require further investigation. However, this potential interaction may
warrant further investigation. In our data, little overlap between 3 and 13-monthold mice is observed. This is most likely due to a low sample size in the 3-month
group which resulted in a low amount of DEGs being identified.
When considering these findings and their biological meaning it is
important to keep in mind certain limitations of this study. One such limitation
likely affecting the correlation between RNA and DNA is that we were not able to
use both DNA and RNA samples from each mouse due to sample quality
concerns. Samples with the highest quantity and quality of RNA/DNA were
selected, while attempting to limit the number of non-overlapping animals
between DNA and RNA analysis to 2 or less. Another challenge to analyse the
data regarding the samples used is that no validation experiments certifying that
the isolated cells from the brain were in fact microglia. Due to low cell counts
from isolations and limited number of animals, all possible sources of DNA and
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RNA from each cell isolation had to be preserved with the intent of validating
representative isolations experiments at a later date. One caveat to the data
presented is that interpreting immune function such as cytokine expression from
RNA levels has proven to be inconsistent with protein levels381. The model used
also presents some limitations to our study, since we are studying immune
function and the murine immune system differs from humans in some significant
ways such as toll receptors, nitric oxide synthase, cytokines, and cytokine
receptors382. These difference between human and mouse may influence the
translatability of results observed in this study. All data presented in this study are
in silico results from high-throughput sequencing and as such will require wet lab
validation likely through pyrosequencing to measure methylation sites and
reverse transcription polymerase chain reaction (RT-PCR) to measure gene
transcription levels.
Despite its limitations, this investigation has identified interesting
candidates for further evaluation in regard to α-syn-induced microglial activation
and associated progression of PD. The possible influence α-syn has on genomic
methylation patterns may act as a feedback loop based on the regulatory role
methylation plays in the genes expression and this possibility warrants further
investigation. Investigation into the Epx genes involvement in collagen
degradation via serpine may be important insight into microglia’s role of synaptic
regulation in the progression of PD. In order to better understand the biological
implications of the data presented, similar analysis involving other phenotypic
time points for in this model system would be necessary.
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In summary, from the data presented we have shown that α-syn
overexpression can induce methylation changes in microglia in the mThy1-α-syn
model of PD. At 3 months, or pre-parkinsonian, these mice show an increase in
cell mobility and inflammatory functions related to activation of microglia early on.
While at 13 months, immune and mobility related functions are still present but
metabolic functions are more prevalent and linked to neurodegenerative disease
annotation as well. Despite observed changes in functional terms being similar
between methylation and gene expression, there was a low amount of correlation
between these changes. Intronic CpGs at 13 months were the only significant
correlation with gene expression with an increase in methylation correlating to a
decrease in expression. Few genes were differentially expressed at both 3 and
13 months however, the conserved change in Epx may warrant further
investigation.
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CHAPTER V
DISCUSSION
The goal of the first study was to identify a possible common underlying
cause of DPN across models, species, and time points. This study was executed
using a unified analysis pipeline to examine eight publicly available microarray
datasets from sciatic nerve tissue and identify highly conserved pathways
associated to DPN. DEGs related to DPN were identified between non-diabetic
and diabetic samples in murine models, and non-progressive and progressive
human samples. DEG lists were constructed into literature association networks,
which were graphically compared between human and each murine network to
obtain shared subnetworks. Identified subnetworks were merged and subjected
to pathway and centrality analysis. The top 50 of multiple measures of centrality
identified the 64 most central genes which showed enrichment of 272 canonical
pathways. Network and cluster analysis of the most central pathways revealed
themes such as apoptosis, inflammatory response, degradation, as well as
immune and kinase signaling were the most involved in the network. These
conserved pathways are likely the key responses in DPN and provide new
therapeutic targets for the potential treatment of DPN, a disorder that remains
without a drug intervention to date.
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The second study of this dissertation focused on the SHD STZ model of
T1DM by examining gene expression changes in tissues associated with DN and
DPN at 16 weeks. RNA-sequencing was used to examine expression changes in
renal glomerulus and cortex (DN) as well as sciatic nerve and dorsal root ganglia
(DPN) following RNA extraction and library preparation. Lists of DEGs were
analyzed using IPA to describe enriched pathways represented in each tissue.
Overlap of DEGs and Pathways were examined with 244 genes and 38
pathways being conserved across three or more tissues. The conserved
pathways included PTEN signaling, PI3K signaling, adipogenesis pathway, acute
phase response signaling, and colorectal cancer metastasis signaling. Of the 244
genes, 188 of them were directionally concordant. The 188 concordant genes
were analyzed using IPA and subjected to network analysis, which identified
clusters relating to oxidative stress, cell cycle, and immune response. These
findings provide transcriptomic profiles of complication-prone tissue in the SHD
STZ model and support previously identified factors influencing microvascular
complications in T1DM.
Our findings regarding DPN in both studies largely agree with the
established literature regarding this complication246,247,383–385. Various cellular
stress mechanisms have been implicated in DPN such as hyperglycemia,
dyslipidemia, hypoxia, ischemia, vascular insufficiency, metabolic syndrome,
impaired insulin signalling, and inflammation as summarized by this review386.
The data presented here largely revolve around the role of inflammation. Diabetic
patients have been shown to experience chronic inflammation through both
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RAGE and TLR activation by circulating high levels of glycation end products216–
220

. Lipid signaling involvement in the immune response has also been

established in the literature and diabetic patients have been shown to display
dyslipidemia387. The first study, which examined multiple models of DPN,
observed a possible central role involving LXR/RXR signaling which is
responsible for regulating lipid metabolism, inflammation, as well as cholesterol
efflux and catabolism225–228. While our second study did not observe a similar
change in our model of type 1 diabetes, other studies regarding unified
complication analysis have observed changes in PPAR-γ signaling which is also
a lipid metabolism regulatory pathway388. It is possible these changes are unique
to the type 2 diabetes form of DPN, since therapeutic strategies such as a PPARγ agonist (pioglitazone)199 did not yield any benefit in STZ-treated mice (data not
shown). Strict glycemic control is also less beneficial in slowing the progression
of DPN in patients with type 2 diabetes than it is in type 1 patients230 suggesting
some differences between these diseases despite symptom similarity.
Many proposed stress mechanisms can be linked to the chronic
inflammation in both type 1 and type 2 diabetes. Hyperglycemia and dyslipidemia
may induce an inflammatory response389 and hypoxic or ischemic conditions can
drive immune cell dysregulation390. One of the main mechanisms of the immune
response to eliminate pathogens is via production of reactive oxygen species391
which have been shown to be neurotoxic392. Largely the role of inflammation in
the progression of DPN remains unclear despite supporting evidence in the
studies presented. However, this is currently being explored both
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experimentally198 as well as in clinical trials involving the use of non-steroidal
anti-inflammatory drugs (salsalate) in type 1 diabetic patients
(https://clinicaltrials.gov/ct2/show/NCT02936843).
In the third study of this dissertation, an overexpression model of PD was
used to investigate the methylation and gene expression changes induced by αsyn in microglia. Microglia were isolated from mThy1-Asyn mice at 3 and 13
months for DNA and RNA extraction. Generated libraries from this procedure
were used for RRBS and RNA-sequencing, respectively. These transgenic mice
have been shown to present markers of neuroinflammation as early as 1 month
and begin to show motor and non-motor symptoms at 3 months similar to a preparkinsonian phenotype. Reduction in dopamine levels and a more severe
phenotype can be observed at 14 months indicating an early stage Parkinson’s
phenotype. However, this model of PD has not been shown to have a reduction
in total number of dopaminergic neurons as is observed in PD patients96,104.
The mThy1-Asyn mice at 3 months, or pre-parkinsonian stage,
demonstrate an increase in cell mobility and inflammatory functions related to
activation of microglia. These results are congruent with the established
phenotype of these mice at 3 months with increased levels of neuroinflammation.
The early stage PD phenotype observed in mice at 13 months demonstrated
enrichment in immune and cell mobility functions as well, but the majority of
functional terms are related to metabolism and mitochondria dysfunction.
Mitochondrial dysfunction has well established literature support its role in PD
and is the target of many chemically induced models and genetic forms of
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PD30,57. However, it has also been shown to create a feedback loop by promoting
inflammation while many pro-inflammatory mediators may disrupt mitochondrial
activity372.
Despite similar functional enrichment in methylation and gene expression
changes observed at both time points, there was very little correlation between
changes in methylation and observed expression changes. Intronic CpGs in our
13-month dataset held a negative correlation with the associated DEGs. Nine
genes were differentially expressed at both 3 and 13 months with 5 concordant
and 4 discordantly expressed. The concordant gene list was associated with
inflammatory genes related to recruitment and chemotaxis. The discordant genes
may indicate progressive changes in the course of disease such as the
involvement of Epx which may influence microglia activity through its interaction
with serpine.
While these studies examine inherently different systems in DPN and PD,
there is evidence supporting systemic inflammatory events influencing the
neurocognitive decline in Alzheimer’s Disease393. By monitoring TNF-α serum
levels in Alzheimer’s patients Holmes et al. observed a 2- and 4-fold increase in
cognitive decline associated with acute and system inflammatory events,
respectively. In healthy individuals systemic infections lead to a sickness
behavior associated with decreased appeptite394 and lethargy395 but these
responses are often short lived up and not thought to have long-term
consequences. It is possible that in the elderly or a diseased state, microglia are
influenced by their microenvironment into a prepared state leading to a more
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profound inflammatory response that contributes to disease symptoms and
progression. Studies examining activated microglia in neurodegenerative models,
at the first sign of behavioral changes, have shown chemokine ligand 2 (CCL2) to
be one of the early activated inflammatory mediators396. Investigation into CCL2
null mice have shown that microglia have a less dramatic inflammatory response
than wild type mice397. This evidence may implicate CCL2 signaling in the
prepared microglia status proposed. Further investigation into the communication
between the peripheral and central immune system and the influence it may have
on the nervous system would provide valuable insight into the progression of
neurodegenerative conditions.
Future Directions
In order to further investigate the role of inflammation in DPN it would be
useful to further characterize DPN progression in the non-obese diabetic (NOD)
mouse which is an immunodeficient mouse strain. The NOD mouse displays
hyperalgesia at 8 weeks and hypoalgesia at 12 weeks suggesting development
of neuropathic pain and may represent DPN progression133,152. A possible DPN
comparison between the NOD mouse, SHD STZ-treated model of T1DM, a
healthy wild-type control, and mice treated with a non-steroidal anti-inflammatory
drug (NSAID) as well as STZ would yield valuable information on the involvement
of inflammation. These models, assuming they had the same background, would
provide similar systems with varying levels of inflammation or immune response.
The NOD mouse is considered immune deficient, STZ treatment along with a
NSAID would knockdown immune activity to a lesser degree than the NOD
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mutation, and STZ treatment alone would provide a T1DM model with a fully
functioning immune system. Measurements of disease progression and severity
of symptoms would offer insight into the physiologic contribution that
inflammation may or may not have on DPN. Transcriptomic analysis may provide
insight into molecular mechanistic difference within the disease system in the
absence or presence of an immune response. This would also open avenues for
addition research into potential immune specific therapeutic targets by
investigating DEGs only present when immunodeficient models (NOD and
NSAID-treated) are compared with a healthy immune system in the STZ model. If
the NOD mouse does not demonstrate symptomatic DPN naturally then an
alternative approach is to use STZ to induce a more severe T1DM phenotype
associated with DPN.
Insight into the role inflammation has on the progression of T2DM
associated DPN could also be obtained by exacerbating the already low grade
inflammation that is experienced with diabetes using a treatment regimen with an
inflammatory stimulus143,398,399. Ideally, RAGE135 would be targeted rather than
engaging another aspect of the immune system; however, pharmacological
agents that currently target this receptor consist of only antagonists400. A study
examining the progression of DPN in a model of T2DM, such as the db/db
mouse, compared to a healthy wild-type control, LPS-treated db/db, NSAIDtreated db/db, and RAGE antagonists-treated db/db would provide a scale of
differing levels of immune response. This could allow a way to determine the
level of contribution inflammation has to DPN progression.
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Further insight into the role that neuroinflammation plays in the mThy1Asyn phenotype and the methylation and expression changes induced by α-syn
in microglia can be approached in multiple ways. The current approach has
indicated some promising results and is worthy of being applied in another study
examining further time points in these animals such as at one month before
appearance of symptoms, after 14 months following the loss of 40% of striatal
dopamine, and a midway time point around 7 months would all yield interesting
results. Studies involving a higher number of animals and biological validation of
sampling would likely yield more insight than the current study provides into the
methylation and expression changes that α-syn can induce. Another interesting
option is the use of a CSF1R inhibitor such as PLX3397 to deplete the brain of
the mThy1-Asyn mouse of microglia401. The use of CSF1R inhibitors to reduce
microglia proliferation has been shown to improve recovery after CNS
injury402,403. In our system, it would provide a way to examine the rate of
progression of symptoms in the absence of microglia to evaluate the influence
inflammation has disease progression. This may also uncover underlying causes
and new therapeutic targets by eliminating a confounding factor in examination of
the condition.
There has been shown to be an increased prevalence of peripheral neuropathy
in PD compared to age matched controls404. It may be worth investigating if the
mThy1-Asyn mouse also experiences peripheral neuropathy. A simple ELISA on
blood samples from the mThy1-Asyn would establish if this model experiences
peripheral inflammation similar to what is observed in PD patients405. The
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aggregate α-syn pathology has been observed in the peripheral nervous system
of the mThy1-Asyn mouse which is likely to engage the peripheral immune
system similar to what is observed in the CNS. If these mice experience
peripheral inflammation and neuropathy, then a possible unified analysis of the
above described studies could provide thorough insight into the interaction
between the nervous and the immune system. A similar approach could be
investigating the cognitive and neurodegenerative status of a chronic
inflammation model such as the interleukin 10 (IL-10) knockout mouse.
Limitations of the Work Presented in this Dissertation
The research presented in this dissertation supports the involvement and
contribution of inflammation and the immune response in progression of
neurodegeneration. The limitations of the work discussed in this dissertation are
presented as follows.
In the first study, the murine models of DPN that were used were on
varied backgrounds. The genetic background of mice has been shown to affect
the progression of neuropathy and presentation of symptoms in murine model
systems158. All data used in this study was publicly available after being used in
other publications and were not originally designed to be compared but were
processed through a unified pipeline to allow comparison between datasets.
However, generation of these model animals on a unified background strain for
the purposes of this study were not feasible so this is a caveat of any information
gathered from these results. Another limitation in both studies related to DPN is
that the sciatic nerve biopsy process taken from the animals includes Schwann
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cells during the RNA isolation. Much of the signal captured from both RNA
expression analysis performed originated from Schwann cells surrounding the
sciatic nerve.
The use of a murine model when examining inflammatory changes should
always be considered a caveat since the murine immune system differs from
humans in some significant ways such as toll receptors, nitric oxide synthase,
cytokines, and cytokine receptors just to name a few which may influence the
results observed in this study382. All data presented in these studies are in silico
results from high throughput sequencing and as such will require technical
validation and would be strongly supported by biological validation experiments.
Summary Conclusions
The work presented in this dissertation strongly implicates inflammation as
a contributing factor to neurodegenerative conditions of both the peripheral and
central nervous system (Figure 25). Analysis of transcriptomic data from multiple
models of DPN to human patients identified clusters of terms related to
inflammation, degradation, apoptosis, as well as kinase and immune signaling as
conserved changes across multiple time points, models, and species of DPN.
Further analysis into the STZ model of T1DM across multiple complication-prone
tissues identified clusters related to DNA-damage response, oxidative stress, and
immune response between diabetic nephropathy and DPN. These results
suggest that peripheral inflammation may be an underlying cause of DPN. α-syn
overexpression-induced methylation and gene expression changes are indicative
of an M1 microglia phenotype in concert with symptomatic progression of PD.
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These results warrant further investigation into the role inflammation plays on the
progression of neurodegenerative disease and the neuro-microenvironment in
both the central and peripheral nervous systems.
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Figure 25. Summary Figure. The biological systems displayed within the human
body include the nervous system and immune system (www.innerbody.com).
Red areas highlight the nervous tissue of interest for this dissertation. Each
study’s results are summarized by their final network figures. The first study
found immune signaling, inflammation, apoptosis, and degradation as conserved
centrally influential pathways in both diabetic patients and mouse models of
DPN. The second study examined both nephropathy and neuropathy associated
with diabetes in an STZ-induced mouse model to identify DNA damage
response, oxidative stress, immune response, cell cycle signaling, as well as
salvage and biosynthesis pathways as being influenced in both complications.
The third study examined the microglia from an α-synuclein overexpression
mouse model of Parkinson’s disease. Microglial changes associated with
aberrant α-synuclein included an inflammatory response, cellular metabolism
dysfunction, as well as cell cycle and proliferation. These results may indicate a
vulnerability of nervous tissue to an inflammatory environment.
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